UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q



þ	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended ~~March~~June 3130, 2017



¨	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number: 000-33283

THE ADVISORY BOARD COMPANY

(Exact name of registrant as specified in its charter)



Delaware		52-1468699
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

2445 M Street, NW, Washington, D.C.		20037
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 266-5600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Table of Contents

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

As of ~~May~~August 1, 2017, the registrant had outstanding 40,~~583~~685,~~660~~446 shares of Common Stock, par value $0.01 per share.

Table of Contents

THE ADVISORY BOARD COMPANY

INDEX TO FORM 10-Q

	Page No.
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements	1
Consolidated Balance Sheets as of March 31, 2017 (unaudited) and December 31, 2016	1
Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016	1
Unaudited Consolidated Statements of Operations for the Three Months Ended March 31, 2017 and 2016	2
Unaudited Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2017 and 2016	2
Unaudited Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2017 and 2016	3
Unaudited Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2017 and 2016	3
Unaudited Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016	4
Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016	4
Notes to Unaudited Consolidated Financial Statements	5
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2021
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	2932
ITEM 4. Controls and Procedures	3033
PART II. OTHER INFORMATION	3134
ITEM 1A. Risk Factors	31
ITEM 1. Legal Proceedings	34
ITEM 6. Exhibits	31
ITEM 1A. Risk Factors	34
Signatures	32
ITEM 6. Exhibits	34
Signatures	35

Table of Contents

PART I. FINANCIAL INFORMATION



Item 1.	Financial Statements.

THE ADVISORY BOARD COMPANY AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

	March 31, 2017			December 31, 2016
	June 30, 2017			December 31, 2016
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	~~150~~144,~~080~~033		$	91,151
Membership fees receivable, net	~~548~~574,~~491~~442			605,517
Prepaid expenses and other current assets	22,~~375~~251			18,965
Total current assets	~~720~~740,~~946~~726			715,633
Construction in progress	8697,~~828~~966			63,368
Property and equipment, net	~~162~~155,~~668~~020			171,281
Intangible assets, net	~~250~~244,~~036~~907			255,053
Deferred incentive compensation and other charges	6359,~~556~~432			72,178
Goodwill	737,023			739,507
Equity method investments	1310,~~711~~180			19,858
Total assets	$	2,~~034~~045,~~768~~254		$	2,036,878
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Deferred revenue, current	$	~~537~~545,~~464~~275		$	564,237
Accounts payable and accrued liabilities	71,~~805~~480			67,702
Accrued incentive compensation	2418,~~845~~469			25,521
Debt, current	5663,~~554~~764			49,347
Total current liabilities	~~690~~698,~~668~~988			706,807
Deferred revenue, net of current portion	~~145~~135,~~236~~628			170,357
Deferred income taxes	8788,~~630~~310			89,013
Debt, net of current portion	~~458~~437,~~592~~251			472,739
Financing obligation	8697,~~828~~966			63,368
Other long-term liabilities	1721,~~398~~038			17,550
Total liabilities	1,~~486~~479,~~352~~181			1,519,834
Stockholders’ equity:
Preferred stock, par value $0.01; 5,000,000 shares authorized, zero shares issued and outstanding	—			—
Common stock, par value $0.01; 135,000,000 shares authorized, 40,391,162 and 40,192,980 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	404			402
Common stock, par value $0.01; 135,000,000 shares authorized, 40,650,932 and 40,192,980 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	406			402
Additional paid-in capital	~~794~~797,~~293~~328			782,399
Accumulated deficit	(~~247~~232,~~310~~563		)	(266,218		)
Accumulated other comprehensive income	~~1,029~~902			461
Total stockholders’ equity	~~548~~566,~~416~~073			517,044
Total liabilities and stockholders’ equity	$	2,~~034~~045,~~768~~254		$	2,036,878

The accompanying notes are an integral part of these consolidated balance sheets.

Table of Contents

THE ADVISORY BOARD COMPANY AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue	$	~~194~~200,~~539~~299		$	~~200~~198,~~735~~382		$	394,838		$	399,117
Costs and expenses:
Cost of services, excluding depreciation and amortization	98101,~~642~~788			9596,~~949~~440			200,430			192,389
Member relations and marketing	3233,~~855~~241			32,~~395~~718			66,096			65,113
General and administrative	3944,~~088~~475			3132,~~828~~219			83,563			64,047
Depreciation and amortization	2221,~~334~~645			1918,~~767~~917			43,979			38,684
Operating income	1,620			20,796
Operating (loss) income	(850		)	18,088			770			38,884
Other expense:
Interest expense	(4,~~500~~730		)	(4,~~821~~389		)	(9,230		)	(9,210		)
Other income, net	233			61
Other (expense) income, net	(90		)	(923		)	143			(862		)
Total other expense, net	(4,~~267~~820		)	(45,~~760~~312		)	(9,087		)	(10,072		)
(Loss) income before benefit (provision) for income taxes and gains (losses) from equity method investments	(25,~~647~~670		)	1612,~~036~~776			(8,317		)	28,812
Benefit (provision) for income taxes	~~724~~2,681			(54,~~663~~870		)	3,405			(10,533		)
Gains (losses) from equity method investments	2117,~~577~~736			(34411		)	39,313			(445		)
Net income	$	1914,~~654~~747		$	107,~~339~~495		$	34,401		$	17,834
Earnings per share
Net income per share—basic	$	0.4936		$	0.2519		$	0.85		$	0.44
Net income per share—diluted	$	0.4836		$	0.2518		$	0.83		$	0.43
Weighted average number of shares outstanding:
Basic	40,~~253~~586			4140,~~492~~365			40,421			40,928
Diluted	41,~~041~~460			4140,~~873~~570			41,252			41,222

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

THE ADVISORY BOARD COMPANY AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017		2016
Net income	$	1914,~~654~~747		$	107,~~339~~495		$	34,401	$	17,834
Other comprehensive income (loss):
Other comprehensive (loss) income:
Net unrealized gain (loss) on cash flow hedges, net of income tax (benefit) expense of $311 and $(1,568) for the three months ended March 31, 2017 and 2016, respectively	568			(2,437		)
Net unrealized (loss) gain on cash flow hedges, net of income tax (benefit) expense of $(104) and $(392) for the three months ended June 30, 2017 and 2016, respectively; and $207 and $(1,960) for the six months ended June 30, 2017 and 2016, respectively	(126		)	(433		)	441		(2,870		)
Comprehensive income	$	2014,~~222~~621		$	7,~~902~~062		$	34,842	$	14,964

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

THE ADVISORY BOARD COMPANY AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Three Months Ended March 31,
	Six Months Ended June 30,
	2017			2016
Cash flows from operating activities:
Net income	$	1934,~~654~~401		$	1017,~~339~~834
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2243,~~334~~979			1938,~~767~~684
Amortization of debt issuance costs	~~341~~561			~~340~~566
Deferred income taxes	24,~~359~~794			(48881		)
Excess tax deficiency/(benefit) from stock-based awards	207			(1,269		)
Excess tax benefit from stock-based awards	(288		)	(633		)
Stock-based compensation expense	511,~~711~~325			614,~~982~~947
Gain on partial sale of equity method investment	(2342,~~392~~312		)	—
Losses from equity method investments	12,~~815~~999			34445
Changes in operating assets and liabilities (net of the effect of acquisitions):
Membership fees receivable	5731,~~026~~074			514,~~389~~948
Prepaid expenses and other current assets	(3,~~428~~247		)	47,~~414~~370
Deferred incentive compensation and other charges	913,~~423~~290			811,~~214~~408
Deferred revenue	(5153,~~894~~691		)	(5735,~~794~~056		)
Accounts payable and accrued liabilities	(1020,~~067~~089		)	(1110,~~596~~738		)
Acquisition-related earn-out payments	(196		)	(1,432		)
Accrued incentive compensation	(~~676~~7,053		)	(124,~~876~~408		)
Other long-term liabilities	~~(550~~2,388		)	~~(260~~27		)
Net cash provided by operating activities	2817,~~667~~935			2723,~~204~~081
Cash flows from investing activities:
Purchases of property and equipment	(716,~~970~~287		)	(919,~~632~~877		)
Capitalized external-use software development costs	(~~734~~1,285		)	(~~836~~1,608		)
Cash paid for acquisitions	—			(1,900		)
Cash received from partial sale of equity method investment	4171,~~366~~871			—
Net cash provided by (used in) investing activities	3254,~~662~~299			(1223,~~368~~385		)
Cash flows from financing activities:
Pay down of debt	(7,187		)	(7,187		)
Proceeds from debt	—			17,000
Proceeds from issuance of common stock from exercise of stock options	5,686			3,019
Pay down of debt	(21,562		)	(14,375		)
Withholding of shares to satisfy employee tax withholding for vested restricted stock units	(797		)	(396		)
Proceeds from issuance of common stock from exercise of stock options	7,389			3,100
Proceeds from issuance of common stock under employee stock purchase plan	84			120
Withholding of shares to satisfy employee tax withholding on stock-based compensation	(5,173		)	(3,432		)
Proceeds from issuance of common stock under employee stock purchase plan	180			256
Acquisition-related earn-out payments	(186		)	(3,600		)
Excess tax benefits from stock-based awards	—			~~1,269~~633
Purchases of treasury stock	—			(2753,~~449~~616		)
Net cash used in financing activities	(219,~~400~~352		)	(3454,~~224~~034		)
Net increase (decrease) in cash and cash equivalents	5852,~~929~~882			(1954,~~388~~338		)
Cash and cash equivalents, beginning of period	91,151			71,825
Cash and cash equivalents, end of period	$	~~150~~144,~~080~~033		$	5217,~~437~~487

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

THE ADVISORY BOARD COMPANY AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Business description and basis of presentation

The Advisory Board Company (individually and collectively with its subsidiaries, the “Company”) provides best practices research and insight, technology, data-enabled services, and consulting services, through discrete programs to hospitals, health systems, independent medical groups, pharmaceutical and biotechnology companies, health care insurers, medical device companies, and colleges, universities, and other health care-focused organizations and educational institutions. Members of each subscription-based membership program are typically charged a separate fixed annual fee and have access to an integrated set of services that may include best practices research studies, executive education, proprietary content databases and online tools, daily online executive briefings, original executive inquiry services, cloud-based software applications, data-enabled services, and consulting and management services.

The unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company uses the equity method to account for equity investments in instances in which it owns common stock and has the ability to exercise significant influence, but not control, over the investee and for all investments in partnerships or limited liability companies where the investee maintains separate capital accounts for each investor. All significant intercompany transactions and balances have been eliminated. Certain items in the prior period financial statements have been reclassified for comparative purposes to conform to the current period presentation.

In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the consolidated financial position, results of operations, and cash flows as of the dates and for the periods presented have been included. The consolidated balance sheet presented as of December 31, 2016 has been derived from the financial statements that have been audited by the Company’s independent registered public accounting firm. The consolidated results of operations for the three and six months ended ~~March~~June 3130, 2017 may not be indicative of the results that may be expected for the Company’s fiscal year ending December 31, 2017, or any other period.

Table of Contents

Note 2. Recent accounting pronouncements

Recently adopted

In March 2016, the Financial Accounting Standards Board ("FASB") issued accounting guidance relating to stock-based compensation. The guidance simplifies various aspects of the accounting for share-based payments. The amendments impact net income, earnings per share, and the statement of cash flows. The guidance is effective for annual reporting and interim periods beginning after December 15, 2016, with early adoption permitted. The Company adopted this standard as of January 1, 2017 using a modified retrospective approach, which requires the cumulative effect of initially applying the standard to be recorded as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application. In connection with the adoption of this guidance, the Company elected to no longer calculate an estimate of expected forfeitures and began recognizing forfeitures as they occurred, which resulted in a cumulative-effect net decrease of $0.7 million to retained earnings with ~~the~~an offset of $1.2 million to additional paid-in capital and an increase of $0.5 million in deferred tax assets. Upon adoption, all excess tax benefits and tax deficiencies are recognized as income tax expense or benefit in the consolidated statements of operations. In addition, excess tax benefits ~~will~~are no longer be presented within cash flows from financing activities but instead ~~will~~are be presented in cash flows from operating activities in the consolidated statements of cash flows. Prior to adoption, the excess tax benefits and tax deficiencies were recorded to additional paid-in capital and excess tax benefits were not recorded until they were able to be utilized.

Recently issued

In May 2014, the FASB issued accounting guidance related to revenue recognition. The new standard supersedes most of the existing revenue recognition guidance under GAAP, and requires revenue to be recognized when goods or services are transferred to a customer in an amount that reflects the consideration a company expects to receive. The new standard may require more judgment and estimates relating to the recognition of revenue, which could result in additional disclosures to the financial statements. The new standard will be effective for annual and interim reporting periods beginning after December 15, 2017, with an option that permits companies to adopt the standard as early as the original effective date of December 31, 2016. Early application prior to the original effective date is not permitted. The Company will adopt the standard on January 1, 2018 using the modified retrospective approach. While the potential impacts of the new standard are still being assessed, the Company currently believes the new standard will affect the Company's accounting for contract acquisition costs and arrangements that include variable consideration. The Company is currently evaluating the effect that the standard will have on its remaining revenue. The Company continues to update its assessment of the impact of the standard and related updates to the consolidated financial statements, and will disclose material impacts when known.

While the potential impacts of the new standard are still being assessed, the Company currently believes the new standard will impact the Company's accounting for deferred costs and arrangements that include variable consideration. The Company is currently evaluating the effect that the standard will have on its remaining revenue. The Company continues to update its assessment of the impact of the standard and related updates to the consolidated financial statements, and will note material impacts when known.

In January 2016, the FASB issued accounting guidance related to the recognition and measurement of financial assets and liabilities. The guidance requires, among other things, that entities measure equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) at fair value, with changes in fair value recognized in net income. Under the new guidance, entities will no longer be able to recognize unrealized holding gains and losses on available-for-sale equity securities in other comprehensive income, and will no longer be able to use the cost method of accounting for equity securities that do not have readily determinable fair values. The guidance for classifying and measuring investments in debt securities and loans is not affected. The guidance eliminates certain disclosure requirements related to financial instruments measured at amortized cost and adds disclosures related to the measurement categories of financial assets and financial liabilities. The guidance is effective for annual periods beginning after December 15, 2017. Early adoption is permitted only for certain portions of the guidance. The adoption of this guidance by the Company is not expected to have a material impact on its consolidated financial statements.

In February 2016, the FASB issued accounting guidance ~~relating~~related to leases. The guidance requires that lessees recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than twelve months. The new guidance also requires disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The guidance is effective for annual reporting and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In August 2016, the FASB issued accounting guidance relating to the statement of cash flows. The guidance clarifies how certain cash receipts and cash payments are presented in the statement of cash flows. The guidance is effective for annual reporting and interim periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In January 2017, the FASB issued accounting guidance which clarifies the definition of a business in order to assist entities in evaluating whether transactions should be accounted for as acquisitions (or dispositions) of assets or businesses. The guidance is effective for annual reporting and interim periods beginning after December 15, 2017. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Table of Contents

In January 2017, the FASB issued accounting guidance simplifying the test of goodwill impairment. The guidance eliminates Step 2 of the goodwill impairment test, which calculates the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will be required to record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e. Step 1). The guidance is effective for annual ~~reporting~~ and interim reporting periods beginning after December 15, ~~2017~~2019, with early adoption permitted. The ~~Company~~adoption isof ~~currently~~this ~~evaluating~~guidance by the ~~impact~~Company ofis ~~the~~not ~~new~~expected ~~guidance~~to have a material impact on its consolidated financial statements.

In January 2017, the FASB issued accounting guidance simplifying the test of goodwill impairment. The guidance eliminates Step 2 of the goodwill impairment test, which calculates the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will be required to record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., Step 1). The guidance is effective for annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted. The adoption of this guidance by the Company is not expected to have a material impact on its consolidated financial statements.

In February 2017, the FASB issued accounting guidance related to gains and losses from the derecognition of nonfinancial assets which clarifies the scope of asset derecognition guidance and accounting for partial sales of nonfinancial assets. The guidance is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In May 2017, the FASB issued accounting guidance related to changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in Topic 718. The guidance is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance by the Company is not expected to have a material impact on its consolidated financial statements.

Note 3. Fair value measurements

Financial assets and liabilities

The estimated fair values of financial instruments are determined based on relevant market information. These estimates involve uncertainty and cannot be determined with precision. The Company’s financial instruments consist primarily of cash, cash equivalents, and interest rate swaps. In addition, contingent earn-out liabilities resulting from business combinations are recorded at fair value. The following methods and assumptions are used to estimate the fair value of each class of financial assets or liabilities that is valued on a recurring basis.

Cash and cash equivalents. This class of financial assets includes all cash and liquid investments with an original maturity of three months or less from the date acquired. The carrying amount approximates fair value because of the short maturity of these instruments. Cash equivalents also consist of money market funds with fair values based on quoted market prices. The Company’s cash and cash equivalents are held at major commercial banks.

Contingent earn-out liabilities. This class of financial liabilities represents the Company’s estimated fair value of the contingent earn-out liabilities related to acquisitions based on probability assessments of certain performance achievements during the earn-out periods. The performance targets are specific to the operation of the acquired company subsequent to the acquisition. These inputs are considered key estimates made by the Company that are unobservable because there are no active markets to support them. Contingent earn-out liabilities are included in accounts payable and accrued liabilities and other long-term liabilities on the consolidated balance sheets.

Interest rate swaps. The Company uses interest rate swaps to manage interest rate risk. The fair values of interest rate swaps are determined using the market standard methodology of discounting the future variable cash payments, or receipts, over the life of the agreements. The variable interest rates used in the calculation of projected receipts are based on observable market interest rate curves. See Note 7, "Debt."

Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The valuation can be determined using widely accepted valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). As a basis for applying a market-based approach in fair value measurements, GAAP establishes a fair value hierarchy that prioritizes into three broad levels the inputs to valuation techniques used to measure fair value. The following is a brief description of those three levels:

• Level 1—Quoted prices in active markets for identical assets or liabilities.

• Level 2—Observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

• Level 3—Unobservable inputs that are supported by little or no market activity, such as discounted cash flow methodologies.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the observability of valuation

Table of Contents

inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no significant transfers between Level 1, Level 2, or Level 3 during the three months ended March 31, 2017 or 2016.Measurements

The following table presents information about the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities, and fair values determined by Level 2 inputs utilize quoted prices in inactive markets for identical assets or liabilities obtained from readily available pricing sources for similar instruments. The fair values determined by Level 3 inputs are unobservable values which are supported by little or no market activity, such as discounted cash flow methodologies. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. It is the Company's policy to recognize transfers between levels of the fair value hierarchy, if any, at the end of the reporting period. There have been no such transfers during any of the periods presented.

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the related classifications are as follows (in thousands):

	Fair value as of March 31,		Fair value measurement as of March 31, 2017using fair value hierarchy
(in thousands)	Fair value as of June 30,		Fair value measurement as of June 30, 2017using fair value hierarchy
	2017		Level 1		Level 2		Level 3
Financial assets
Cash and cash equivalents (1)	$	~~150~~144,~~080~~033	$	~~150~~144,~~080~~033	$	—	$	—
Interest rate swaps (2)	1,~~845~~589		—		1,~~845~~589		—
Financial liabilities
Contingent earn-out liabilities (3)	1,~~185~~235		—		—		1,~~185~~235
	Fair valueas of December 31,		Fair value measurement as of December 31, 2016using fair value hierarchy
	2016		Level 1		Level 2		Level 3
Financial assets
Cash and cash equivalents (1)	$	91,151	$	91,151	$	—	$	—
Interest rate swaps (2)	1,044		—		1,044		—
Financial liabilities
Contingent earn-out liabilities (3)	1,164		—		—		1,164

—————————————


(1)	Fair value is based on quoted market prices.


(2)	Fair value is determined using market standard models with observable inputs.


(3)	This fair value measurement is based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value using the income approach. In developing these estimates, the Company considered certain performance projections, historical results, and general macroeconomic environment and industry trends.

Contingent earn-out liabilities

The Company's fair value estimate of the earn-out liability related to the Company’s acquisition of Clinovations, LLC (“Clinovations”) in November 2014 was $4.5 million as of the date of acquisition. The Clinovations earn-out liability is affected by changes in estimates regarding expected operating results through the evaluation periods, which will end on December 31, 2017 with payments extending through April 2018. As of ~~March~~June 3130, 2017, 62,269 shares have been issued to pay a portion of the earn-out liability under the terms of the acquisition agreement. The maximum payout of the earn-out liability is $9.5 million, while the minimum payment is $0. Based on the results of Clinovations’ operating results, the fair value of the remaining contingent obligation for Clinovations as of ~~March~~June 3130, 2017 was estimated at $0.9 million.

The Company's fair value estimate of the earn-out liability related to the Company’s acquisition of ThoughtWright, LLC d/b/a GradesFirst (“GradesFirst”) in December 2014 was $3.6 million as of the date of acquisition. The Company paid $4.0 million during the ~~three~~six months ended ~~March~~June 3130, 2016 in satisfaction of its remaining obligation.

The Company entered into an earn-out agreement in connection with its acquisition of Southwind Health Partners, L.L.C. and Southwind Navigator, LLC (together, “Southwind”) in December 2009. The Company paid $1.0 million during the three months ended March 31, 2016 in satisfaction of its remaining obligation.

Changes in the fair value of the contingent earn-out liabilities subsequent to the acquisition date, including changes arising from events that occurred after the acquisition date, such as changes in the Company’s estimate of performance achievements, discount rates, and stock price, are recognized in earnings in the periods during which the estimated fair value changes.

Table of Contents

	Three Months Ended March 31,
	2017			2016
Beginning balance	$	1,164		$	7,250
Addition due to acquisition	—			357
Fair value change in Clinovations contingent earn-out liability (1)	239			(1,070		)
Fair value change in other contingent earn-out liabilities (1)	164			—
Southwind earn-out payments	—			(1,032		)
Other earn-out payments	(382		)	—
GradesFirst earn-out payments	—			(4,000		)
Ending balance	$	1,185		$	1,505

The Company entered into an earn-out agreement in connection with its acquisition of Southwind Health Partners, L.L.C. and Southwind Navigator, LLC (together, “Southwind”) in December 2009. The Company paid $1.0 million during the six months ended June 30, 2016 in satisfaction of its remaining obligation.

The following table represents a reconciliation of the change in the contingent earn-out liabilities for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017			2016
Beginning balance	$	1,185	$	1,505	$	1,164		$	7,250
Addition due to acquisition	—		—		—			357
Fair value change in Clinovations contingent earn-out liability (1)	36		1,750		275			680
Fair value change in other contingent earn-out liabilities (1)	14		25		178			25
Southwind earn-out payments	—		—		—			(1,032		)
Other earn-out payments	—		—		(382		)	—
GradesFirst earn-out payments	—		—		—			(4,000		)
Ending balance	$	1,235	$	3,280	$	1,235		$	3,280

—————————————


(1)	Amounts were recognized in cost of services on the consolidated statements of operations.

Financial instruments not recorded at fair value on a recurring basis

Equity method investments. The Company's equity method investments represent the Company's ownership interest in Evolent Health, Inc. and its subsidiary, Evolent Health LLC. The fair value of the Company's ownership interest in Evolent Health, Inc. and its subsidiary prior to any discount was $~~161~~149.06 million as of ~~March~~June 3130, 2017 based on the closing price of the Class A common stock of Evolent Health, Inc. on that date as reported on the New York Stock Exchange. For further information, see Note 6, "Equity method investments"." The fair value of the Company's equity method investments is measured quarterly for disclosure purposes. The Company's equity method investments are recorded at fair value only if an impairment charge is recognized.

Credit facilities. The Company estimates that the fair value of its credit facilities was $~~520~~507.76 million as of ~~March~~June 3130, 2017. The fair value was determined based on discounting the future expected variable cash payments over the life of the loan. The variable interest rates used in the calculation are based on observable market interest rates. The credit facilities would be classified as Level 2 within the fair value hierarchy if they were measured at fair value.

Non-financial assets and liabilities

Certain assets and liabilities are not measured at fair value on an ongoing basis, but instead are measured at fair value on a non-recurring basis, so that such assets and liabilities are subject to fair value adjustments in certain circumstances (such as when there is evidence of impairment). During the ~~three~~six months ended ~~March~~June 3130, 2017 and 2016, no fair value adjustments or material fair value measurements were required for non-financial assets or liabilities.

Note 4. Property and equipment

Property and equipment consists of leasehold improvements, furniture, fixtures, equipment, capitalized internal-use software development, and acquired developed technology. Property and equipment is stated at cost, less accumulated depreciation and amortization. In certain membership programs, the Company provides software applications under a hosting arrangement where the software application resides on the Company’s or its service providers’ hardware. The members do not take delivery of the software and only receive access to the software during the term of their membership agreement. Software development costs that are incurred in the preliminary project stage are expensed as incurred. During the development stage, direct consulting costs and payroll and payroll-related costs for employees that are directly associated with each project are capitalized and amortized over the estimated useful life of the software once placed into operation. Capitalized software is amortized using the straight-line method over its estimated useful life, which is generally five years. Replacements and major improvements are capitalized, while maintenance and repairs are charged to expense as incurred.

The acquired developed technology, which includes acquired software, databases, and analytics, is classified as software within property and equipment because the developed software application, database, or analytic resides on the Company’s or its service providers’ hardware. Amortization for acquired developed technology is included in depreciation and amortization on the Company’s consolidated statements of operations. Developed technology obtained through acquisitions is amortized using the straight-line method over the estimated useful life used in determining the fair value of the assets at acquisition. As of March 31, 2017, the weighted average useful life of existing acquired developed technology was approximately eight years.

Table of Contents

~~The~~amortized ~~amount~~using ofthe ~~acquired~~straight-line ~~developed~~method ~~technology~~over ~~amortization~~its ~~included~~estimated inuseful ~~depreciation~~life, ~~and~~which ~~amortization~~is ~~for~~generally ~~the~~five ~~three~~years. ~~months~~Replacements ~~ended~~and ~~March 31,~~major ~~2017~~improvements ~~and~~are ~~March 31~~capitalized, ~~2016~~while ~~was~~maintenance ~~approximately~~and ~~$2.1~~repairs ~~million~~are ~~and~~charged ~~$2.3~~to ~~million,~~expense ~~respectively~~as incurred.

~~Furniture~~The acquired developed technology, ~~fixtures~~which includes acquired software, databases, and ~~equipment~~analytics, ~~are~~is ~~depreciated~~classified ~~using~~as software within property and equipment because the ~~straight-line~~developed ~~method~~software ~~over~~application, database, or analytic resides on the ~~estimated~~Company’s ~~useful~~or ~~lives~~its service providers’ hardware. Amortization of ~~the~~acquired ~~assets,~~developed ~~which~~technology ~~range~~is ~~from~~included ~~three~~in todepreciation ~~seven~~and ~~years~~amortization on the Company’s consolidated statements of operations. ~~Leasehold~~Developed ~~improvements~~technology ~~are~~obtained ~~depreciated~~through acquisitions is amortized using the straight-line method over the ~~shorter~~estimated ofuseful ~~the~~life ~~estimated~~used ~~useful~~in ~~lives~~determining the fair value of the assets orat acquisition. As of June 30, 2017, the ~~lease~~weighted ~~term~~average useful life of existing acquired developed technology was approximately eight years. ~~There~~The ~~are~~amount noof ~~capitalized~~acquired ~~leases~~developed technology amortization included in ~~property~~depreciation and ~~equipment,~~amortization ~~net~~ for the ~~periods~~three ~~presented~~months ended June 30, 2017 and 2016 was approximately $2.6 million and $2.3 million, respectively. The amount of ~~depreciation~~acquired ~~expense~~developed ~~recognized~~technology onamortization ~~furniture,~~included ~~fixtures,~~in depreciation and ~~equipment~~amortization ~~during~~for the ~~three~~six months ended ~~March~~June 3130, 2017 and ~~March 31,~~ 2016 was approximately $54.97 million and $5.4.6 million, respectively.

~~Internally~~Furniture, ~~developed~~fixtures, ~~capitalized~~and ~~software~~equipment ~~related~~are todepreciated using the ~~Company's~~straight-line ~~hosted~~method ~~software~~over isthe ~~classified~~estimated asuseful ~~software~~lives ~~within~~of ~~property~~the ~~and~~assets, ~~equipment~~which ~~and~~range ~~has~~from anthree ~~estimated~~to ~~useful~~seven ~~life~~years. ofLeasehold ~~five~~improvements ~~years.~~are Asdepreciated ofusing ~~March 31,~~the ~~2017~~straight-line ~~and~~method ~~December~~over ~~31,~~the ~~2016,~~shorter of the ~~carrying~~estimated ~~value~~useful lives of ~~internally~~the ~~developed~~assets ~~capitalized~~or ~~software~~the ~~was~~lease ~~$73~~term.6 ~~million~~There ~~and~~are ~~$75.2~~no ~~million~~capitalized leases included in property and equipment, ~~respectively~~net for the periods presented. ~~Amortization~~The amount of depreciation expense ~~for~~recognized ~~internally~~with ~~developed~~respect ~~capitalized~~to ~~software~~furniture, ~~for~~fixtures, and equipment during the three months ended ~~March~~June 3130, 2017 and ~~March 31~~2016 was $5.1 million and $5.4 million, ~~2016~~respectively. ~~recorded~~The inamount of depreciation expense recognized with respect to furniture, fixtures, and ~~amortization~~equipment onduring the ~~accompanying~~six ~~statements~~months ofended ~~operations~~June 30, ~~was~~2017 ~~approximately~~and 2016 was $810.59 million and $610.48 million, respectively.

Internally developed capitalized software related to the Company's hosted software is classified as software within property and equipment and has an estimated useful life of five years. As of June 30, 2017 and December 31, 2016, the carrying value of internally developed capitalized software was $74.1 million and $75.2 million, respectively. Amortization expense for internally developed capitalized software for the three months ended June 30, 2017 and 2016 recorded in depreciation and amortization on the consolidated statements of operations was approximately $7.0 million and $5.5 million, respectively. Amortization expense for internally developed capitalized software for the six months ended June 30, 2017 and 2016 recorded in depreciation and amortization on the consolidated statements of operations was approximately $13.8 million and $11.9 million, respectively.

Property and equipment consists of the following (in thousands):

	As of
	March 31, 2017			December 31, 2016
	June 30, 2017			December 31, 2016
Leasehold improvements	$	69,~~777~~709		$	69,465
Furniture, fixtures, and equipment	70,~~963~~463			70,362
Software	~~237~~244,~~305~~839			231,952
Property and equipment, gross	~~378~~385,~~045~~011			371,779
Accumulated depreciation and amortization	(~~215~~229,~~377~~991		)	(200,498		)
Property and equipment, net	$	~~162~~155,~~668~~020		$	171,281

The Company evaluates its long-lived assets for impairment when changes in circumstances exist that suggest the carrying value of a long-lived asset may not be fully recoverable. If an indication of impairment exists, and the Company’s net book value of the related assets is not fully recoverable based upon an analysis of its estimated undiscounted future cash flows, the assets are written down to their estimated fair value. The Company recognized a $0.7 million loss on the disposal of property and equipment during the three months ended June 30, 2017 related to the announced restructuring plan. For further information regarding the restructuring plan, see Note 14, "Costs of exit or disposal." There was no material impairment loss recognized on long-lived assets during the three and six months ended ~~March~~June 3130, 2017 and ~~March 31,~~ 2016, respectively.

Construction in progress. In December 2015, the Company entered into a lease for its new corporate headquarters, which is currently being constructed in Washington D.C. The lease has an anticipated start date of mid-2019, with a 16-year initial term and $446.1 million of lease payments. The Company has concluded that it is the deemed owner of the building (for accounting purposes only) during the construction period and that the lease qualifies for build-to-suit accounting. Accordingly, the Company has recorded a construction-in-progress asset, net of $8698.80 million for which there is a corresponding construction financing obligation of $8698.80 million recorded in the consolidated balance sheet as of ~~March~~June 3130, 2017. The Company will continue to increase the construction-in-progress asset and corresponding long-term liability as additional building costs are incurred by the landlord during the construction period. Upon completion of the construction, the Company will evaluate whether ~~or not~~ this arrangement meets the criteria for sale-leaseback accounting treatment.

Table of Contents

Note 5. Goodwill and intangibles

Included in the Company’s goodwill and intangibles balances are goodwill and acquired intangibles, as well as internally developed capitalized software for sale. Goodwill is not amortized because it has an estimated indefinite life. Goodwill is reviewed for impairment at least annually as of October 1, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes that no such impairment indicators existed during the ~~three~~six months ended ~~March~~June 3130, 2017 or 2016, respectively. There was no impairment of goodwill recorded in the ~~three~~six months ended ~~March~~June 3130, 2017 or 2016, respectively.

The following illustrates the change in the goodwill balance for the ~~three~~six months ended ~~March~~June 3130, 2017 (in thousands):

Balance as of December 31, 2016	$	739,507
Acquisitions	—
Adjustment related to Royall acquisition (1)	(2,484		)
Balance as of March 31, 2017	$	737,023
Balance as of June 30, 2017	$	737,023

—————————————


(1)	Represents an immaterial adjustment to the blended state tax rate used in the purchase price allocation resulting in a reduction to deferred tax liabilities and a reduction of goodwill.

Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range from 2 years to 17 years. As of ~~March~~June 3130, 2017, the weighted average remaining useful life of acquired intangibles was approximately 1312.19 years. As of ~~March~~June 3130, 2017, the weighted average remaining useful life of internally developed intangibles was approximately 3.40 years.

The gross and net carrying balances and accumulated amortization of intangibles are as follows (in thousands):

		As of March 31, 2017							As of December 31, 2016
		As of June 30, 2017							As of December 31, 2016
	Weightedaverageuseful life	Grosscarryingamount		Accumulatedamortization			Netcarryingamount		Grosscarryingamount		Accumulatedamortization			Netcarryingamount
Intangibles
Internally developed software for sale:
Capitalized software	5.0	$	2021,~~766~~318	$	(1011,~~868~~735	)	$	9,~~898~~583	$	20,034	$	(9,998	)	$	10,036
Acquired intangibles:
Developed software	5.2	9,450		(8,~~700~~825		)	~~750~~625		9,450		(8,575		)	875
Customer relationships	16.2	277,710		(4751,~~332~~628		)	~~230~~226,~~378~~082		277,710		(42,978		)	234,732
Trademarks	8.6	14,900		(6,~~215~~507		)	8,~~685~~393		14,900		(5,923		)	8,977
Non-compete agreements	3.8	1,400		(1,400		)	—		1,400		(1,400		)	—
Customer contracts	4.7	6,449		(6,225		)	224		6,449		(6,016		)	433
Customer contracts	4.7	6,449		(6,124		)	325		6,449		(6,016		)	433
Total intangibles		$	329,827	$	(84,920	)	$	244,907	$	328,543	$	(73,490	)	$	255,053
Total intangibles		$	330,675	$	(80,639	)	$	250,036	$	329,943	$	(74,890	)	$	255,053

Amortization expense for intangible assets for the three months ended ~~March~~June 3130, 2017 and ~~March 31,~~ 2016, recorded in depreciation and amortization on the consolidated statements of operations, was approximately $5.87 million. Amortization expense for intangible assets for the six months ended June 30, 2017 and 2016, recorded in depreciation and amortization on the consolidated statements of operations, was approximately $511.74 million~~, respectively~~. The following approximates the aggregate amortization expense to be recorded in depreciation and amortization on the consolidated statements of operations for the remaining ~~nine~~six months of the fiscal year ending December 31, 2017, for each of the following fiscal years ending December 31, 2018 through 2021, and thereafter: $1611.93 million, $21.78 million, $20.12 million, $18.89 million, and $17.89 million, respectively, and $154.78 million thereafter.

Table of Contents

Note 6. Equity method investments

As of ~~March~~June 3130, 2017, the Company held a 42.56% equity interest in Evolent Health LLC (“Evolent LLC”) and a 76.23% equity ownership interest in Evolent Health, Inc. (“Evolent Inc.”), which had no material operations outside of its 8396.91% ownership interest in Evolent LLC. These investments are accounted for under the equity method, with the Company’s proportionate share of the investees’ losses recognized in the consolidated statements of operations. The Company has the right to designate two individuals to Evolent Inc.'s board of directors, who were the Company’s Chief Financial Officer and an unaffiliated designee of the Company as of ~~March~~June 3130, 2017.

~~During the three months ended March 31, 2017, the Company recognized in the consolidated statements of operations its proportionate share of the losses of~~ Evolent Inc. of $1.3 million. During the three months ended March 31, 2016, the Company recorded a net gain on its investment of Evolent Inc. of $0.3 million, which consisted of a $1.1 million dilution gain offset by $0.8 million for the Company's share of losses of Evolent Inc. The carrying balance of the Company’s investment in Evolent Inc. was $9.0 million and $10.3 million as of March 31, 2017 and December 31, 2016, respectively. The Company had no unrecorded losses related to its investment in Evolent Inc. as of March 31, 2017.

During the three months ended ~~March~~June 3130, 2017, the Company ~~exchanged~~recognized ~~Evolent LLC B units and Evolent Inc. Class B shares for Evolent Inc. Class A common stock on a one-for-one basis, then immediately sold all the Evolent Inc. Class A shares~~ in ~~an underwritten secondary offering, retaining a 4.5% interest immediately after such sale. Total cash received from~~ the ~~transaction~~consolidated ~~was~~statements ~~$41.4 million and resulted in the recognition~~ of aoperations ~~post-tax~~its ~~gain of $23.4 million. The Company's~~ proportionate share of the losses of Evolent ~~LLC~~Inc. ~~was~~of $1.60 million ~~during the three months ended March 31, 2017~~. During the three months ended ~~March 31~~ June 30, 2016, the Company's ~~recorded~~proportionate ashare ~~net~~of ~~loss~~the onlosses ~~its investment~~ of Evolent ~~LLC~~Inc. ofwas $01.52 million,. ~~which~~The ~~consisted~~Company ~~of a~~recorded $0.93 million ~~dilution gain offset by $1.4 million for the Company's share~~ of ~~the~~these losses ofagainst ~~Evolent~~the ~~LLC.~~remaining ~~The~~ carrying ~~balance~~amount of ~~the~~its ~~Company’s~~ investment inat ~~Evolent LLC was $4.7 million and $9.6 million as of March~~June 3130, ~~2017 and December 31,~~ 2016~~, respectively~~. The ~~Company~~remaining ~~had no unrecorded~~ losses ~~related~~were tonot ~~its~~recorded ~~investment~~as inthey ~~Evolent~~exceeded ~~LLC~~the asCompany's ofinvestment ~~March 31, 2017~~balance.

AtDuring the ~~time~~six ofmonths ~~the~~ended ~~reorganization~~June 30, ~~and initial public offering of Evolent Inc.~~2017, the Company ~~carried~~recognized ~~over its basis~~ in the ~~investment,~~consolidated ~~resulting~~statements inof aoperations ~~significant difference between~~ its ~~basis and its~~ proportionate share inof the ~~equity~~losses of Evolent Inc. As of ~~March~~ ~~31, 2017, the basis difference totaled~~ $~~43.~~2.3 million. ~~and~~During ~~will~~the ~~decrease~~six ~~over~~months ~~time~~ended ~~through~~June ~~amortization~~30, ~~and~~2016, ~~upon~~the ~~any~~Company's ~~sale~~proportionate orshares ~~dilutive~~of ~~transactions.~~the losses of Evolent Inc. ~~gained~~was $2.0 ~~control~~million, of ~~Evolent~~which ~~LLC in the transaction and applied purchase and push down accounting~~$1.1 ~~The~~million was ~~Company~~recognized ~~has~~in ~~excluded~~ the ~~effects~~consolidated ofstatements ~~this accounting in its determination~~ of ~~the equity in Evolent LLC losses~~operations, ~~thereby~~offset ~~reducing~~by ~~its~~a $1.1 ~~share~~million dilution ~~of losses from Evolent LLC for the affected periods~~gain.

~~Because~~The ofcarrying ~~Evolent~~balance ~~LLC's treatment as a partnership for federal income tax purposes, the losses~~ of ~~Evolent LLC pass through to~~ the Company ~~and the other members. The Company'~~’s ~~proportionate~~investment ~~share~~in ~~of the losses of~~ Evolent ~~LLC is recorded net of the estimated tax benefit the Company believes will be realized from the equity in loss of equity method investments on the consolidated statements of operations~~Inc. ~~Historically,~~was ~~the Company had provided a full valuation allowance against the deferred tax asset resulting from these benefits~~$8.0 ~~During~~million ~~the~~and ~~three months ended March 31, 2016, tax benefit of~~ $010.23 million ~~was~~ ~~recorded~~as ~~for the tax effects~~ of ~~current~~June 30, ~~year~~2017 ~~losses~~and ~~received~~December ~~from Evolent LLC. The provision for income taxes from gains (losses) from equity method investments for the three months ended March~~ 31, ~~2017 was $13.6 million~~2016, ~~representing an effective tax rate of 38~~respectively.~~7%.~~ ~~Tax~~The ~~expense~~Company ofhad ~~$14.7~~no ~~million~~unrecorded ~~was~~losses ~~recorded~~related ~~for~~to ~~the~~its ~~tax~~investment ~~effect of the current period gain on sale of shares~~ in Evolent ~~LLC offset by a $1~~Inc.1 ~~million~~as ~~tax benefit for the allocated share~~ of ~~losses from Evolent LLC and Evolent~~June 30, ~~Inc~~2017.

~~The gains (losses) from equity method investments on the consolidated statement of operations for the combined~~ Evolent ~~entities consisted of the following (in thousands):~~LLC

	Three Months Ended March 31,
	2017			2016
Dilution gain	$	—		$	2,026
Gain on partial sale of investment	38,117			—
Allocated share of losses	(2,898		)	(2,221		)
Tax (expense) benefit	(13,642		)	161
Gains (losses) from equity method investments	$	21,577		$	(34	)

During the three and six months ended June 30, 2017, the Company received total cash of $30.5 million and $71.9 million, respectively, from the sale in one transaction in three months ended March 31, 2017 and two transactions in the three months ended June 30, 2017 of shares of Evolent Inc. Class A common stock which the Company received in exchange, on a one-for-one basis, for Evolent LLC Class B common units and shares of Evolent Inc. Class B common stock. The transactions resulted in post-tax gains of $18.9 million and $42.3 million for the three and six months ended June 30, 2017, respectively.

InThe ~~connection~~Company's ~~with~~proportionate share of the losses of Evolent ~~Inc~~LLC was $0.'s8 ~~initial~~million ~~public~~during ~~offering~~the ~~and~~three ~~the~~months ~~related~~ended ~~reorganization~~June 30, 2017. During the ~~Company~~three ~~and~~months ~~certain~~ended June 30, ~~investors~~2016, inthe ~~Evolent~~Company's ~~LLC~~proportionate ~~entered~~share ~~into~~of athe ~~tax~~losses ~~receivables~~of ~~agreement~~Evolent ~~with~~LLC ~~Evolent~~was $1.0 ~~Inc~~million. ~~Under~~The ~~the~~Company ~~terms~~recorded $0.2 million of ~~that~~these ~~agreement,~~losses ~~Evolent~~against ~~Inc.~~the ~~will~~remaining ~~make~~carrying ~~cash~~amount ~~payments~~of toits ~~the~~investment ~~Company~~at ~~and~~June 30, ~~certain~~2016. ~~investors~~The inremaining ~~amounts~~losses ~~equal~~were tonot ~~85%~~recorded ofas ~~Evolent~~they ~~Inc.~~exceeded the Company's ~~actual~~investment ~~tax~~balance. ~~benefit~~The ~~realized~~Company's ~~from~~proportionate ~~various~~share ~~tax~~of ~~attributes~~the ~~related~~losses toof ~~activity~~Evolent ~~before~~LLC ~~the~~was ~~initial public offering~~$2.4 ~~Interest~~million ~~will~~during bethe ~~included~~six onmonths ~~the~~ended ~~tax~~June 30, ~~savings~~2017. atDuring the ~~applicable~~six ~~London~~months ~~interbank~~ended ~~offered~~June 30, ~~rate~~2016, ~~plus~~the ~~100~~Company's ~~basis~~proportionate ~~points.~~share ~~The~~of ~~tax~~the ~~receivables~~losses ~~agreement~~of ~~will~~Evolent ~~generally~~LLC ~~apply~~was $2.5 tomillion, ~~Evolent~~of ~~Inc~~which $1.'s6 ~~taxable~~million was ~~years~~recognized upin tothe ~~and~~consolidated ~~including~~statements ~~the~~of ~~15th~~operations, ~~anniversary~~offset ~~date~~by ofa $0.9 ~~the~~million dilution ~~transaction~~gain. The Asremaining oflosses ~~March 31,~~were ~~2017,~~not recorded as they exceeded the Company's ~~had~~investment balance.

The carrying balance of the Company’s investment in Evolent LLC was $2.2 million and $9.6 million as of June 30, 2017 and December 31, 2016, respectively. The Company had no unrecorded losses related to its investment in Evolent LLC as of June 30, 2017.

At the time of Evolent Inc.'s initial public offering and related reorganization, the Company carried over its basis in the investment, resulting in a significant difference between its basis and its proportionate share in the equity of Evolent Inc. As of June 30, 2017, the basis difference totaled $43.0 million and will decrease over time through amortization and upon any sale or dilutive transactions. Evolent Inc. gained control of Evolent LLC in the transaction and applied purchase and push down accounting. The Company has excluded the effects of this accounting in its determination of the equity in Evolent LLC losses, thereby reducing its share of losses from Evolent LLC for the affected periods.

Because of Evolent LLC's treatment as a partnership for federal income tax purposes, the losses of Evolent LLC pass through to the Company and the other members. The Company's proportionate share of the losses of Evolent LLC is recorded net of the estimated tax benefit the Company believes will be realized from the equity in loss of equity method investments on the consolidated statements of operations. Historically, the Company had provided a full valuation allowance against the deferred tax asset resulting from these benefits. In the three and six months ended June 30, 2016, tax benefits of $0.1 million and $0.3 million, respectively, were recorded for the tax effects of the current year losses received from Evolent LLC. The provision for income taxes from gains (losses) from equity method investments for the three months ended June 30, 2017 was $9.2 million, representing an effective tax rate of 34.2%. Tax expense of $9.8 million was recorded for the tax effect of the current period gain on sale of shares in Evolent LLC, offset by a $0.6 million tax benefit for the allocated share of losses from Evolent LLC and Evolent, Inc. The provision for income taxes from gains (losses) from equity method investments for the six

Table of Contents

~~not~~months ~~received~~ended ~~any~~June ~~payments~~30, ~~pursuant~~2017 towas ~~the~~$22.9 million, representing an effective tax ~~receivables~~rate ~~agreement~~of 36.8%. AsTax ~~the~~expense ~~amount~~of ~~the~~$24.6 ~~Company~~million ~~will~~was ~~receive~~recorded ~~pursuant~~for to the tax ~~receivables~~effect ~~agreement~~of isthe ~~unknown,~~current ~~the~~period ~~Company~~gain ~~will~~on ~~recognize~~sale ~~payments,~~of ifshares ~~any~~in Evolent LLC, ~~associated~~offset ~~with~~by ~~this~~a ~~agreement~~$1.7 ~~when~~million ~~such~~tax ~~payments~~benefit ~~are~~for ~~received~~the allocated share of losses from Evolent LLC and Evolent, Inc.

The ~~following~~gains is(losses) afrom ~~summary~~equity ofmethod investments on the ~~financial~~consolidated ~~position~~statement of operations for the combined Evolent ~~LLC~~entities asconsisted of the ~~dates~~following ~~presented:~~(in thousands):

	As of
	Three Months Ended June 30,						Six Months Ended June 30,
	March 31, 2017			December 31, 2016
	2017			2016			2017			2016
Assets:
Dilution gain	$	—		$	—		$	—		$	2,026
Current assets	$	339,487		$	154,555
Gain on partial sale of investment	28,736			—			66,853			—
Non-current assets	923,591			921,556
Allocated share of losses	(1,763		)	(511		)	(4,661		)	(2,732		)
Total assets	$	1,263,078		$	1,076,111
Tax (expense) benefit	(9,237		)	100			(22,879		)	261
Liabilities and members’ equity:
Gains (losses) from equity method investments	$	17,736		$	(411	)	$	39,313		$	(445	)
Current liabilities	$	225,815		$	131,926
Non-current liabilities	134,797			24,654
Total liabilities	360,612			156,580
Members’ equity	902,466			919,531
Total liabilities and members’ equity	$	1,263,078		$	1,076,111

~~The~~In ~~following~~connection iswith Evolent Inc.'s initial public offering and the related reorganization, the Company and certain investors in Evolent LLC entered into a ~~summary~~tax receivables agreement with Evolent Inc. Under the terms of that agreement, Evolent Inc. will make cash payments to the ~~operating~~Company ~~results~~and certain investors in amounts equal to 85% of Evolent ~~LLC~~Inc.'s ~~for~~actual tax benefit realized from various tax attributes related to activity before the ~~periods~~initial ~~presented:~~public offering. Interest will be included on the tax savings at the applicable London interbank offered rate plus 100 basis points. The tax receivables agreement will generally apply to Evolent Inc.'s taxable years up to and including the 15th anniversary date of the transaction. As of June 30, 2017, the Company had not received any payments pursuant to the tax receivables agreement. As the amount the Company will receive pursuant to the tax receivables agreement is unknown, the Company will recognize payments, if any, associated with this agreement when such payments are received.

	Three Months Ended March 31,
	2017			2016
Revenue	$	106,238		$	49,449
Cost of revenue (exclusive of depreciation and amortization)	67,528			28,611
Gross profit	$	38,710		$	20,838
Net loss	$	(23,150	)	$	(174,799	)

The following is a summary of the financial position of Evolent LLC as of the dates presented (in thousands):

The following is a summary of the consolidated financial position of Evolent Inc. as of the dates presented:



	As of
	June 30, 2017		December 31, 2016
Assets:
Current assets	$	319,180	$	154,555
Non-current assets	930,407		921,556
Total assets	$	1,249,587	$	1,076,111
Liabilities and members’ equity:
Current liabilities	$	224,432	$	131,926
Non-current liabilities	130,960		24,654
Total liabilities	355,392		156,580
Members’ equity	894,195		919,531
Total liabilities and members’ equity	$	1,249,587	$	1,076,111

	As of
	March 31, 2017		December 31, 2016
Assets:
Current assets	$	217,538	$	264,966
Non-current assets	936,908		934,873
Total assets	$	1,154,446	$	1,199,839
Liabilities and shareholders' equity:
Current liabilities	$	104,439	$	131,941
Non-current liabilities	153,267		155,784
Total liabilities	257,706		287,725
Total shareholders' equity attributable to Evolent Health, Inc.	750,471		702,526
Non-controlling interests	146,269		209,588
Total liabilities and shareholders’ equity	$	1,154,446	$	1,199,839

The following is a summary of the operating results of Evolent LLC for the periods presented (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue	$	107,071		$	56,517		$	213,309		$	105,967
Cost of revenue (exclusive of depreciation and amortization)	67,993			32,779			135,521			61,390
Gross profit	$	39,078		$	23,738		$	77,788		$	44,577

Net loss	$	(20,298	)	$	(12,371	)	$	(43,016	)	$	(187,170	)

Table of Contents

The following is a summary of the consolidated ~~operating~~financial ~~results~~position of Evolent Inc. ~~for~~as of the ~~periods~~dates presented (in thousands):

		Three Months Ended March 31,
	As of
		2017				2016
	June 30, 2017				December 31, 2016
Revenue		$	106,238			$	49,449
Assets:
Cost of revenue (exclusive of depreciation and amortization)		67,528				28,611
Current assets	$	192,620			$	264,966
Gross profit		$	38,710			$	20,838
Non-current assets	945,732				934,873
Loss before income taxes and non-controlling interests		$	(22,744	)		$	(174,799	)
Total assets	$	1,138,352			$	1,199,839
Net loss		$	(23,149	)		$	(173,811	)
Liabilities and shareholders' equity:
Loss attributable to Evolent Health, Inc.		$	(18,012	)		$	(122,740	)
Current liabilities	$	101,760			$	131,941
Non-current liabilities	142,143				155,784
Total liabilities	243,903				287,725
Total shareholders' equity attributable to Evolent Health, Inc.	859,769				702,526
Non-controlling interests	34,680				209,588
Total liabilities and shareholders’ equity	$	1,138,352			$	1,199,839

~~Evolent~~The ~~LLC~~following is ina ~~the~~summary ~~early stages~~ of ~~its business plan and, as a result,~~ the ~~Company~~consolidated ~~expects~~operating ~~both~~results of Evolent Inc. ~~and Evolent LLC to continue to incur losses. The Company’s investments are evaluated~~ for ~~impairment whenever events or changes in circumstances indicate that there may be an other-than-temporary decline in value. As of March 31, 2017,~~ the ~~Company~~periods ~~believes~~presented ~~that no impairment charge is necessary. For additional information on the fair value of the Company’s investment~~ (in ~~the Evolent entities, see Note 3, “Fair value measurements.”~~thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue	$	107,071		$	56,518		$	213,310		$	105,967
Cost of revenue (exclusive of depreciation and amortization)	67,994			32,779			135,523			61,390
Gross profit	$	39,077		$	23,739		$	77,787		$	44,577

Loss before income taxes and non-controlling interests	$	(20,398	)	$	(12,370	)	$	(43,143	)	$	(187,169	)
Net loss	$	(19,698	)	$	(11,999	)	$	(42,848	)	$	(185,810	)
Loss attributable to Evolent Health, Inc.	$	(16,905	)	$	(8,387	)	$	(34,918	)	$	(131,127	)

Evolent LLC is in the early stages of its business plan and, as a result, the Company expects both Evolent Inc. and Evolent LLC to continue to incur losses. The Company’s investments are evaluated for impairment whenever events or changes in circumstances indicate that there may be an other-than-temporary decline in value. As of June 30, 2017, the Company believes that no impairment charge is necessary. For additional information on the fair value of the Company’s investment in the Evolent entities, see Note 3, “Fair value measurements.”

Note 7. Debt

OnThe ~~February 6, 2015, the~~ Company's ~~obtained $675 million of senior secured~~ credit facilities ~~(“credit facilities”) under a credit agreement with a syndicate of lenders. The credit facilities were amended on October 30, 2015. The amended credit facilities~~ consist of (a) a five-year senior secured term loan facility in the principal amount of $475 million (“term facility”) and (b) a five-year senior secured revolving credit facility (“revolving credit facility”) under which up to $200 million principal amount of borrowings and other credit extensions may be outstanding at any time. Amounts drawn under the term facility and revolving credit facilities bear interest, payable quarterly, at an annual rate calculated, at the Company’s option, on the basis of either (a) an alternate base rate plus an initial margin of 1.25% or (b) the applicable London interbank offered rate ("LIBOR") plus an initial margin of 2.25%, subject in each case to margin reductions based on the Company’s total leverage ratio from time to time. As of ~~March~~June 3130, 2017, based on the Company's historical leverage ratio, the interest rate margin was 2.00% and the stated annual interest rate on outstanding borrowings was 23.9923%.

As of ~~March~~June 3130, 2017, there was $100.0 million outstanding under the revolving credit facility and $80.9 million available for future borrowings. As of ~~March~~June 3130, 2017, $19.1 million of standby letters of credit had been issued under the revolving credit facility.

Long-term debt is summarized as follows (in thousands):

	As of March 31, 2017
2.99% term facility due fiscal 2020 ($417,500 face value less unamortized discount of $2,354)	$	415,146
Revolving credit facility	100,000
Less: Amounts due in next twelve months ($57,500 face value less unamortized discount of $946)	(56,554		)
Total long-term debt	$	458,592

The credit agreement contains customary representations and warranties, events of default and financial and other covenants, including covenants that require the Company to maintain a maximum total leverage ratio and a minimum interest coverage ratio. The Company's compliance with the two financial covenants is measured as of the end of each fiscal quarter. The Company was in compliance with these financial covenants as of March 31, 2017.

Interest expense for the three months ended March 31, 2017 and 2016 was $4.5 million and $4.8 million, respectively, inclusive of $0.3 million and $0.3 million, respectively, of amortization of debt issuance costs, and $0.3 million and $0.6 million, respectively, of payments related to the interest rate swaps described below.

Swap agreements

Table of Contents

Long-term debt is summarized as follows (in thousands):



	As of June 30, 2017
3.23% term facility due fiscal 2020 ($403,125 face value less unamortized discount of $2,110)	$	401,015
Revolving credit facility	100,000
Less: Amounts due in next twelve months ($64,688 face value less unamortized discount of $924)	(63,764		)
Total long-term debt	$	437,251

Interest expense for the three months ended June 30, 2017 and 2016 was $4.7 million and $4.4 million, respectively, inclusive of $0.3 million and $0.3 million, respectively, of amortization of debt issuance costs, and $0.2 million and $0.6 million, respectively, of payments related to the interest rate swaps described below. Interest expense for the six months ended June 30, 2017 and 2016 was $9.2 million and $9.2 million, respectively, inclusive of $0.6 million and $0.6 million, respectively, of amortization of debt issuance costs, and $0.5 million and $1.2 million, respectively, of payments related to the interest rate swaps described below.

Swap agreements

Through its term facility, the Company is exposed to interest rate risk. In April 2015, to minimize the impact of changes in interest rates on its interest payments, the Company entered into three interest rate swap agreements with financial institutions to swap a portion of its variable-rate interest payments for fixed-rate interest payments. The interest rate swap derivative financial instruments are recorded on the consolidated balance sheets at fair value, which is based on observable market-based expectations of future interest rates.

At hedge inception, the Company entered into interest rate swap arrangements with notional amounts totaling $287.5 million. The swap was structured to have a declining notional amount which matches the amortization schedule of the term facility. As of ~~March~~June 3130, 2017, the principal amount hedged was $~~258~~251.86 million. The interest rate swap agreements mature in February 2020 and have periodic interest settlements, both consistent with the terms of the Company's term facility. Under this agreement, the Company is entitled to receive a floating rate based on the 1-month ~~London~~LIBOR ~~interbank offered rate~~ and obligated to pay an average fixed rate of 1.282% on the outstanding notional amount. The Company has designated the interest rate swap as a cash flow hedge of the variability of interest payments under its term facility due to changes in the LIBOR benchmark interest rate. The difference between cash paid and received is recorded within interest expense on the consolidated statements of operations.

As of ~~March~~June 3130, 2017 and 2016, the fair value of the interest rate swaps was an asset of $1.86 million and a liability of $34.68 million, respectively, and was recorded within ~~Prepaid~~prepaid expenses and other current assets and other long-term liabilities, respectively, on the Company's consolidated balance sheets. For the three months ended ~~March~~June 3130, 2017 and 2016, the change in fair value of the swaps, net of tax, was ana ~~increase~~decrease of $0.61 million and ~~a decrease of~~ $20.4 million, respectively, and was reported as a component of accumulated other comprehensive income on the consolidated statement of operations. For the ~~three~~six months ended ~~March~~ 31June 30, 2017 and 2016, ~~hedge~~the ~~ineffectiveness~~change ~~recorded~~in ~~within~~fair value of the ~~consolidated~~swaps, ~~statements~~net of ~~operations~~tax, was ~~immaterial~~an increase of $0.4 ~~There~~million and a decrease of $2.9 million, respectively. For the three months and six months ended June 30, 2017 and 2016, there was no material hedge ineffectiveness asrecorded ofwithin ~~March~~the ~~31,~~consolidated ~~2016~~statements of operations. Changes in fair value are reclassified from accumulated other comprehensive income into earnings in the same period in which the hedged item affects earnings.

If, at any time, the swap is determined to be ineffective, in whole or in part, due to changes in the interest rate swap or underlying debt agreements, the fair value of the portion of the swap determined to be ineffective will be recognized as a gain or loss on the consolidated statements of operations for the applicable period.

Table of Contents

Note 8. Stockholders’ equity

The Company is authorized to purchase up to $550 million of the Company's common stock in its cumulative share repurchase program. The Company did not repurchase any shares of its common stock in the three and six months ended ~~March~~June 3130, 2017. The Company repurchased ~~937~~803,~~030~~217 and 1,740,247 shares of its common stock at a total cost of approximately $2726.42 million and $53.6 million, respectively, in the three and six months ended ~~March~~June 3130, 2016, respectively, pursuant to ~~this~~its share repurchase program. The total amount of common stock purchased from inception under the program through ~~March~~June 3130, 2017 was 19,778,800 shares at a total cost of $513.5 million. All such repurchases have been made in the open market, and all repurchased shares have been retired as of ~~March~~June 3130, 2017. No minimum number of shares subject to repurchase has been fixed, and the share repurchase authorization has no expiration date. As of ~~March~~June 3130, 2017, the remaining authorized repurchase amount was $36.5 million.

Note 9. Stock-based compensation

Stock incentive plans

The Company issues awards, including stock options and restricted stock units ("RSUs"), under the Company's 2009 Stock Incentive Plan (the "2009 Plan"). ~~The~~On May 31, 2017, the Company's stockholders approved an amendment to the “2009 Plan” that increased the number of shares of common stock issuable under the plan by 1,000,000 shares. After giving effect to the amendment, the aggregate number of shares of the Company’s common stock available for issuance under the 2009 Plan may not exceed 1011,535,000. As of ~~March 31~~June 30, 2017, there were 12,~~172~~358,~~130~~472 shares available for issuance under the 2009 Plan.

Performance-based RSU grant. On March 28, 2017, the Compensation Committee of the Board of Directors approved a grant of 106,870 RSUs under the 2009 Plan to certain executive officers of the Company. These awards are subject to performance conditions. Awards will vest based on the achievement of adjusted earnings per share targets during the performance periods, which extend through December 31, 2019, with all awards vesting if the highest performance levels are achieved~~, which extend through December 31, 2019~~. The Company has concluded that it is probable that all awards will vest at the highest level of performance. The awards are reflected in the table below.

Stock option activity. During the three months ended March 31, 2017 and 2016, participants exercised 168,078 and 233,030 options, respectively, for a total intrinsic value of $1.9 million and $3.4 million, respectively. Intrinsic value is calculated as the number of shares exercised times the Company’s stock price at exercise less the exercise price of the option.

Table of Contents

Royall inducement plan

During the ~~three~~six months ended ~~March~~June 3130, 2017, the first vesting tranche of the Royall Inducement awards vested in full. AAs ~~total~~of June 30, 2017, the Company continues to expect that 70% to 99% of ~~175~~the remaining performance targets will be achieved based on performance of the Royall programs and services through December 31,~~050~~ ~~nonqualified~~2017, which would result in an additional vesting of 10% of the performance-based stock options and ~~14,570~~10% of the performance-based RSUs ~~vested~~eligible to vest, subject to forfeitures. ~~The~~During ~~RSUs~~the ~~had~~three anmonths ~~intrinsic~~ended ~~value~~March 31, 2017, the Company determined it to be no longer probable that the January 2019 and January 2020 vesting tranches, representing 20% of the awards, would vest. As a result, $0.79 million. ~~Intrinsic~~in ~~value~~compensation isexpense ~~calculated~~related asto these tranches was reversed in the ~~number~~six ofmonths ~~shares~~ended ~~vested~~June 30, ~~times~~2017. ~~the~~The ~~Company’s~~amount ~~closing~~of stock-based ~~price~~compensation onexpense ~~the~~may ~~NASDAQ~~increase ~~Global~~or ~~Select~~decrease ~~Market~~over attime based upon changes in expectations regarding whether the ~~vesting~~applicable ~~date~~performance conditions will be met. OfThe actual amount of expense that the ~~RSUs~~Company ~~vested,~~will ~~5,500~~recognize ~~shares~~is ~~were~~based ~~withheld~~upon Royall's actual results. The option and RSU award activity related to ~~satisfy~~these ~~minimum~~awards ~~employee~~is ~~tax~~reflected ~~withholding.~~in the tables and related disclosure below.

AsStock of March 31, 2017, the Company expects that 70% to 99% of the performance targets will be achieved based on performance of the Royall programs and services through December 31, 2017, which would result in an additional vesting of 10% of the performance-based stock options and 10% of the performance-based RSUs eligible to vest, subject to forfeitures. The Company believes it is no longer probable that the January 2019 and January 2020 vesting tranches, representing 20% of the awards, will vest. As a result, $0.9 million in compensation expense related to these tranches was reversed in the three months ended March 31, 2017. The amount of stock-based compensation expense may increase or decrease over time based upon changes in expectations regarding whether the applicable performance conditions will be met. The actual amount of expense that the Company will recognize is based upon Royall's actual results. The option ~~and RSU awards are reflected in the tables below.~~activity

~~The~~During ~~following~~the ~~table~~six ~~summarizes~~months ~~the~~ended ~~changes~~June 30, in2017 ~~common~~and ~~stock~~2016, participants exercised 288,911 and 237,158 options, ~~outstanding~~respectively, ~~under~~for a total intrinsic value of $2.8 million and $3.5 million, respectively. Intrinsic value is calculated as the number of shares exercised times the Company’s stock ~~incentive~~price ~~plans~~at ~~during~~exercise less the ~~three~~exercise ~~months~~price ~~ended~~of ~~March 31,~~the ~~2017~~option. ~~and 2016:~~

	Number of performance-based options		Weightedaverageexerciseprice		Number ofservice-based options		Weightedaverageexerciseprice
Outstanding, as of December 31, 2015	2,013,325		$	50.42	1,843,110		$	41.73
Granted	319,900		28.20		978,668		28.20
Exercised	—		—		(233,030	)	15.21
Forfeited	(80,370	)	49.92		(22,195	)	53.38
Outstanding, as of March 31, 2016	2,252,855		$	47.28	2,566,553		$	38.88
	Number of performance-based options		Weightedaverageexerciseprice		Number ofservice-based options		Weightedaverageexerciseprice
Outstanding, as of December 31, 2016	2,117,855		$	47.11	2,525,178		$	39.28
Granted	—		—		200,324		46.95
Exercised	—		—		(168,078	)	33.83
Forfeited	(43,497	)	51.18		(31,395	)	40.80
Expired	—		—		—		—
Outstanding, as of March 31, 2017	2,074,358		$	47.02	2,526,029		$	40.24
Exercisable, as of March 31, 2017	521,822		$	35.83	1,089,022		$	42.14

The fair value of the service-based options, valued using a Black-Scholes model, granted during the three months ended March 31, 2017 was estimated at $16.80 per share on the date of grant using the following weighted average assumptions: risk-free interest rate of 2.0%; an expected term of approximately 5.0 years; expected volatility of 37.50%; and dividend yield of 0.0% over the expected life of the option.

During the three months ended March 31, 2017, 319,900 options with market conditions vested. No options with performance and/or market conditions vested during the three months ended March 31, 2016.

Table of Contents

The following table summarizes the changes in ~~RSUs~~common ~~granted~~stock options outstanding under the Company’s stock incentive plans during the ~~three~~six months ended ~~March~~June 3130, 2017 and 2016:

	Number ofperformance-based RSUs		Weighted averagegrant datefair value		Number ofservice-based RSUs		Weighted averagegrant datefair value
	Number of performance-based options		Weightedaverageexerciseprice		Number ofservice-based options		Weightedaverageexerciseprice
Non-vested, December 31, 2015	301,032		$	39.10	839,613		$	52.82
Outstanding, as of December 31, 2015	2,013,325		$	50.42	1,843,110		$	41.73
Granted	17319,~~292~~900		3228.2520		~~278~~1,~~996~~005,756		28.2031
Forfeited	(19,598	)	51.11		(20,172	)	53.89
Exercised	—		—		(237,158	)	15.29
Vested	—		—		(34,771	)	64.23
Forfeited	(215,370	)	49.92		(22,195	)	53.38
Non-vested, March 31, 2016	298,726		$	37.91	1,063,666		$	45.97
Expired	—		—		(17,347	)	51.77
	Number ofperformance-based RSUs		Weighted averagegrant datefair value		Number ofservice-based RSUs		Weighted averagegrant datefair value
Outstanding, as of June 30, 2016	2,117,855		$	47.11	2,572,166		$	38.75
Non-vested, December 31, 2016	257,580		$	35.34	968,084		$	42.13
	Number of performance-based options		Weightedaverageexerciseprice		Number ofservice-based options		Weightedaverageexerciseprice
Granted	106,870		46.95		218,120		46.94
Outstanding, as of December 31, 2016	2,117,855		$	47.11	2,525,178		$	39.28
Forfeited	(29,359	)	51.54		(25,513	)	50.64
Granted	—		—		200,324		46.95
Vested	(14,570	)	49.92		(31,400	)	64.92
Exercised	(18,300	)	49.92		(270,611	)	35.79
Non-vested, March 31, 2017	320,521		$	37.06	1,129,291		$	42.23
Forfeited	(115,044	)	51.19		(135,320	)	39.88
Expired	—		—		—		—
Outstanding, as of June 30, 2017	1,984,511		$	46.85	2,319,571		$	40.31
Exercisable, as of June 30, 2017	492,092		$	34.98	1,178,440		$	43.86

The ~~Company~~fair ~~recognized~~value ~~stock~~of the service-based ~~compensation~~options ~~expense~~granted induring the six months ended June 30, 2017 was estimated at $16.80 per share on the date of grant valued using a Black-Scholes model utilizing the following ~~consolidated~~weighted ~~statements~~average assumptions: risk-free interest rate of ~~operations~~2.0%; ~~line~~an ~~items~~expected ~~for~~term ~~stock~~of ~~options~~approximately 5.0 years; expected volatility of 37.50%; and ~~RSUs~~dividend ~~for~~yield ~~the~~of ~~three~~0.0% ~~months~~over ~~ended~~the ~~March 31,~~expected ~~2017~~life ~~and~~of ~~2016~~the ~~(in~~option. ~~thousands):~~

	Three Months Ended March 31,
	2017		2016
Stock-based compensation expense included in:
Costs and expenses:
Cost of services	$	1,258	$	2,187
Member relations and marketing	1,146		1,114
General and administrative	3,307		3,681
Total costs and expenses	$	5,711	$	6,982

During the six months ended June 30, 2017, 483,520 options with market and/or performance-based conditions vested. No options with performance and/or market conditions vested during the six months ended June 30, 2016.

Restricted stock unit activity

During the six months ended June 30, 2017 and 2016, participants vested in 342,519 and 312,131 RSUs, respectively, for a total intrinsic value of $16.3 million and $10.2 million, respectively. Intrinsic value is calculated as the number of shares vested times the Company’s closing stock price on the NASDAQ Global Select Market at the vesting date. Of the RSUs vested in the six months ended June 30, 2017 and 2016, 106,841 and 106,547 shares, respectively, were withheld to satisfy minimum employee tax withholding.

Table of Contents

The following table summarizes the changes in RSUs granted under the Company’s stock incentive plans during the six months ended June 30, 2017 and 2016:



	Number of performance-based RSUs		Weighted average grant date fair value		Number of service-based RSUs		Weighted average grant date fair value
Non-vested, December 31, 2015	301,032		$	39.10	839,613		$	52.82
Granted	23,580		32.28		467,177		30.36
Forfeited	(33,429	)	50.77		(41,089	)	47.73
Vested	—		—		(312,131	)	51.43
Non-vested, June 30, 2016	291,183		$	37.21	953,570		$	42.49

	Number of performance-based RSUs		Weighted average grant date fair value		Number of service-based RSUs		Weighted average grant date fair value
Non-vested, December 31, 2016	257,580		$	35.34	968,084		$	42.13
Granted	106,870		46.95		266,203		47.76
Forfeited	(35,800	)	51.52		(71,374	)	44.85
Vested	(14,570	)	49.92		(327,949	)	46.58
Non-vested, June 30, 2017	314,080		$	36.77	834,964		$	41.94

The Company recognized stock-based compensation expense in the following consolidated statements of operations line items for stock options and RSUs for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Stock-based compensation expense included in:
Costs and expenses:
Cost of services	$	1,829	$	2,493	$	3,087	$	4,680
Member relations and marketing	1,134		1,387		2,280		2,501
General and administrative	2,651		4,085		5,958		7,766
Total costs and expenses	$	5,614	$	7,965	$	11,325	$	14,947

There are no stock-based compensation costs capitalized as part of the cost of an asset.

As of ~~March~~June 3130, 2017, $5649.02 million of total unrecognized compensation cost related to outstanding options and non-vested RSUs was expected to be recognized over a weighted average period of 2.85 years.

Note 10. Income taxes

The Company's effective tax rates were 2747.43% and 3538.31% for the three months ended ~~March~~June 3130, 2017 and 2016, respectively., ~~The~~and ~~decrease~~40.9% inand ~~the~~36.6% ~~current~~for ~~period tax rate was primarily due to~~ the ~~Company’s~~six ~~tax~~months ~~loss~~ended ~~position combined with the new stock-based compensation guidance~~June 30, ~~see~~2017 ~~Note~~and 22016, ~~"Recent~~respectively. ~~accounting~~The ~~pronouncements",~~increase ~~where~~in ~~differences between tax deductions generated and recognized compensation expense from stock option exercises and restricted stock vesting now flow through~~ the ~~Company's~~2017 period tax ~~rate,~~rates ~~and~~was aprimarily ~~change~~due into the Company’s ~~estimated Research and Development~~ tax ~~credit~~loss ~~from~~position ~~$1.8~~as ~~million~~compared to ~~$3.5~~income ~~million~~positions in the ~~three~~comparative ~~months~~periods ~~ended~~of ~~March 31,~~ 2016 ~~and 2017, respectively~~.

The Company uses a more-likely-than-not recognition threshold based on the technical merits of the tax position taken for the financial statement recognition and measurement of a tax position. If a tax position does not meet the more-likely-than-not initial recognition threshold, no benefit is recorded in the financial statements. The Company does not expect that the total amounts of unrecognized tax benefits will significantly change within the next 12 months. The Company classifies interest and

1718

Table of Contents

not initial recognition threshold, no benefit is recorded in the financial statements. The Company does not expect that the total amounts of unrecognized tax benefits will significantly change within the next 12 months. The Company classifies interest and penalties on any unrecognized tax benefits as a component of the provision for income taxes. The Company recognized an immaterial amount of interest in the consolidated statements of operations in the three and six months ended ~~March~~June 3130, 2017 and ~~March 31,~~ 2016, respectively. The Company files income tax returns in U.S. federal and state and foreign jurisdictions. With limited exceptions, the Company is no longer subject to U.S. federal, state, and local tax examinations for filings in major tax jurisdictions before 2014.

Note 11. Earnings per share

Basic earnings per share is computed by dividing net income by the number of weighted average common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the number of weighted average common shares and potentially dilutive common shares outstanding during the period. The number of potential common shares outstanding is determined in accordance with the treasury stock method. Certain potential common share equivalents were not included in the computation because their effect was anti-dilutive.

A reconciliation of basic to diluted weighted average common shares outstanding is as follows (in thousands):

	Three Months Ended March 31,
	Three Months Ended June 30,		Six Months Ended June 30,
	2017	2016	2017	2016
Basic weighted average common shares outstanding	40,~~253~~586	4140,~~492~~365	40,421	40,928
Effect of dilutive outstanding stock-based awards	~~788~~874	~~381~~205	831	294
Diluted weighted average common shares outstanding	41,~~041~~460	4140,~~873~~570	41,252	41,222

In the three months ended ~~March~~June 3130, 2017 and 2016, 10.29 million and 2.48 million shares, respectively, related to share-based compensation awards have been excluded from the calculation of the effect of dilutive outstanding stock-based awards shown above because their effect was anti-dilutive. In the six months ended June 30, 2017 and 2016, 1.3 million and 2.6 million shares, respectively, related to share-based compensation awards have been excluded from the calculation of the effect of dilutive outstanding stock-based awards shown above because their effect was anti-dilutive.

As of ~~March~~June 3130, 2017, the Company had 2.1.5 million nonqualified stock options and 0.3 million RSUs that contained either performance or market conditions, or both, and therefore ~~are~~were treated as contingently issuable awards. As of ~~March~~June 3130, 2016, the Company had 2.21 million nonqualified stock options and 0.3 million RSUs that contained either performance or market conditions and were treated as contingently issuable awards. These awards are excluded from diluted earnings per share until the reporting period in which the necessary conditions are achieved. To the extent all necessary conditions have not yet been satisfied, the number of contingently issuable shares included in diluted earnings per share will be based on the number of shares, if any, that would be issuable if the end of the reporting period were the end of the contingency period. A total of ~~129~~146,~~655~~525 and 19128,~~971~~336 incremental shares related to contingently issuable awards were included within the diluted earnings per share calculations for the three and six months ended ~~March~~June 3130, 2017 ~~and 2016~~, respectively, as the related performance goals were met as of the balance sheet date. A total of 19,971 contingently issuable shares were included within the diluted earnings per share calculations for the three and six months ended June 30, 2016 as the related performance goals were met as of June 30, 2016.

Note 12. Supplemental cash flow

A summary of supplemental cash flow information for the three and six months ended ~~March 31~~June 30, 2017 and 2016 is presented below (in thousands):

	Three Months Ended March 31,
	Six Months Ended June 30,
	2017		2016
Cash paid (received) for:
Income taxes	$	65,648	$	~~(245~~2,841	)
Interest	$	37,~~687~~629	$	37,~~754~~097
Non-cash activities:
Increase in estimated cost of construction of a building under a build-to-suit lease	$	2334,~~460~~598	$	412,~~906~~354

1819

Table of Contents

Note 13. Related parties

In June 2009, the Company invested in the convertible preferred stock of a private company that provides technology tools and support services to health care providers, including the Company’s members, and entered into a reseller licensing agreement with that company. As disclosed in Note 2, "Summary of significant accounting policies" of the Company's consolidated financial statements included in its ~~2016~~Annual Report on Form 10-K ~~filing,~~for the ~~relationship~~year ~~with~~ended December 31, 2016, the private company is considered to be a related party.

The Company ~~paid~~made ~~$1.5~~payments ~~million and $1.2 million~~ to the private company under ~~its~~the reseller agreement ~~which~~of is$1.1 ~~included~~million inand ~~cost~~$1.0 ofmillion ~~services~~for on the three ~~consolidated~~months ~~statement~~ended June 30, of2017 ~~operations~~and 2016, respectively, and $2.6 million and $2.2 million for the ~~three~~six months ended ~~March~~June 3130, 2017 and 2016, respectively. The payments are included in cost of services on the consolidated statements of operations.

Note 14. Costs of ~~Exit~~exit or ~~Disposal~~disposal

~~During~~In ~~the~~January ~~three months ended March 31,~~ 2017, the Company announced a restructuring plan. In connection with the ~~restructuring~~ plan, the Company is reducing its workforce as a part of a broader effort to more closely align operating expenses with its long-term strategic initiatives. Additionally, the Company isclosed ~~closing~~ four offices and is completing a gradual wind-down process, to be completed by the end of ~~fiscal~~the year ending December 31, 2017, for several products.

As a result of the restructuring plan, the Company incurred one-time severance and other employee benefit costs of $42.8 million ~~recognized~~and $7.7 million during the three and six months ended June 30, 2017, respectively. For the three and six months ended June 30, 2017, the Company recorded $0.8 million and $0.8 million, respectively, of these amounts in cost of services, $0.1 million and $0.1 million, respectively, of these amounts in member relations and marketing expense, respectively, and $1.9 million and $6.8 million, respectively, of these amounts in general and administrative inexpense on the ~~accompanying~~consolidated statements of operations. The Company expects to recognize approximately $42.56 million of additional one-time severance and other employee benefit costs through the remainder of the year ~~ended~~ending December 31, 2017. ~~The~~Lease ~~Company~~exit ~~did~~costs ~~not~~of ~~incur~~$3.2 ~~any~~million ~~material~~were ~~lease~~incurred ~~exit costs~~ during both the three and six months ended ~~March~~June 3130, 2017, ~~and~~respectively. ~~does~~Lease ~~not~~exit ~~have~~costs ~~any~~of ~~material~~up ~~accruals~~to ~~recorded~~$2.0 onmillion ~~the~~are ~~consolidated~~expected ~~balance~~to ~~sheet~~be asrecognized ofduring ~~March 31,~~the ~~2017~~remainder ~~related~~of to the ~~restructuring~~year ~~plan~~ended December 31, 2017. The Company ~~expects~~does tonot ~~recognize~~have upany tomaterial ~~$11.0~~accruals ~~million~~recorded ofon ~~one-time~~the ~~lease~~consolidated ~~exit~~balance ~~costs~~sheet ~~during~~as ~~the~~of June 30, ~~remainder~~2017 related ofto the ~~year~~restructuring ~~ended December 31, 2017~~plan. No exit or disposal costs were incurred in the three and six months ended ~~March 31~~June 30, 2016.

Note 15. Subsequent events

On ~~May~~August 13, 2017, a purported class-action lawsuit was filed in the ~~Company~~U.S. ~~sold~~District aCourt ~~portion~~for Southern District of New York naming as defendants the Company and two of its ~~interest~~executive inofficers, ~~Evolent~~one ~~LLC~~of whom is a director. ~~This~~In ~~transaction~~the ~~reduced~~complaint, the plaintiff alleges that the Company'’s ~~ownership~~public statements about its business and operations between January 21, 2015 and February 23, 2016 contained material misstatements and omissions in ~~Evolent~~violation ~~LLC~~of ~~from~~Section 4.10(b) of the Securities Exchange Act of 1934 and Rule 10b-5% tothereunder 4which artificially inflated the Company’s stock price.~~1%. Total~~ ~~cash~~In ~~received~~addition ~~from~~to compensatory damages in an unspecified amount and attorneys’ fees, the ~~transaction~~action ~~was~~seeks ~~$6.2~~such ~~million~~relief as the district court deems just and proper. The Company ~~expects~~intends to ~~recognize~~vigorously adefend ~~gain~~this onaction. The Company has not established reserves or ranges of possible loss related to this ~~sale~~legal ~~and~~matter isbecause, ~~currently~~as ~~evaluating~~of the ~~impact~~date of this report, the ~~sale~~matter ~~will~~does ~~have~~not onrelate to a probable loss and the ~~recorded~~amount ~~value~~or range of ~~its~~loss ~~investment~~is not reasonably estimable.

19On August 7, 2017, Evolent Inc. announced a public offering of $175.0 million of its Class A common stock. If and when that transaction is consummated, the Company’s ownership percentage in Evolent Inc. and Evolent LLC will decrease. The Company is currently evaluating the effect that this dilution will have on its investment and will finalize its accounting for this transaction if and when it is consummated.

Table of Contents



Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Unless the context indicates otherwise, references in this management’s discussion and analysis to “we,” “our,” and “us” mean The Advisory Board Company and its consolidated subsidiaries.

This management’s discussion and analysis includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. These statements can sometimes be identified by our use of such forward-looking words as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would,” and similar words and expressions. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the results, performance, or achievements expressed or implied by the forward-looking statements, including the factors discussed under “Item 1A. Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2016, or the “2016 Form 10-K.” We undertake no obligation to update any forward-looking statements, whether as a result of circumstances or events that arise after the date the statements are made, new information, or otherwise.

Executive Overview

We are a leading provider of insight-driven performance improvement solutions to the rapidly changing health care and education industries. Through our subscription-based membership programs, software, data-enabled services, and consulting capabilities, we leverage our intellectual capital to help our approximately 5,700 clients, which we refer to as our members, solve their most critical business problems. ~~As of March 31, 2016, we served approximately 5,700 members.~~

We provide members with best-practice industry research, and insights that they need to thrive in a dynamic market. We then help to guide and support our members in the implementation of these best practices through proprietary, high-value technology, services, and consulting capabilities. All of our programs are rooted in best practices and extend across four key areas:

•

Best practices research. Our best practices research and insight programs provide the foundation for all of our other programs. These programs are focused on understanding industry dynamics, identifying best-demonstrated management practices, critically evaluating widely-followed but ineffective practices, and analyzing emerging trends within the health care and education industries. We communicate and teach best practices across our broad network through independent forums for each key leadership constituency.


•	Technology. Our cloud-based software applications allow members to combine insights derived from our best practices research with their own operational and financial data and third-party and proprietary data to benchmark performance; identify and assess revenue, cost, quality, and performance improvement opportunities; and implement identified best practices.


•	Data-enabled services. We draw on our extensive data assets, distinctive technology platforms, proven processes, and deep expertise gained over years of experience to apply best practices and enablement services to directly produce results for our members.


•	Consulting services. Our consulting services programs assist our members’ own efforts to set strategic direction, address key operational challenges, and improve their performance. We deploy our experts to work side-by-side with members implementing best practice solutions and driving change in their organizations.

Members of each subscription-based membership program are typically charged a separate fixed annual fee and have access to an integrated set of services that may include best practices research studies, executive education, proprietary content databases and online tools, daily online executive briefings, original executive inquiry services, cloud-based business intelligence and software applications, tech-enabled services, and consulting and management services.

Our membership business model allows us to create value for our members by providing proven solutions to common and complex problems as well as high-quality content and innovative software on a broad set of relevant issues. Our revenue increased 1.0% and declined 31.1% in the three and six months ended ~~March~~June 3130, 2017 over the three and six months ended ~~March~~June 3130, 2016, respectively. Our adjusted contract value ~~increased~~decreased 14.54% to $~~756~~723.2 million as of ~~March~~June 3130, 2017 from $~~744~~756.76 million as of ~~March~~June 3130, 2016. We define contract value as the aggregate annualized revenue attributable to all agreements in effect at a particular date, without regard to the initial term or remaining duration of any such agreement, excluding the impact of the ~~to-be-exited~~ programs ~~announced~~we intend to exit in conjunction with ~~our~~the restructuring and strategic alternatives plan we announced on January 3, 2017. In each of our programs, we generally invoice and collect fees in advance of accrual revenue recognition.

2021

Table of Contents

Our operating costs and expenses consist of cost of services, member relations and marketing expense, general and administrative expenses, and depreciation and amortization expense.

•

Cost of services includes the costs associated with the production and delivery of our products and services, consisting of compensation for research, creative, data, and analysis personnel, consultants, software developers, and in-house faculty; costs of the organization and delivery of membership meetings, teleconferences, and other events; production and distribution of published materials; technology license fees; costs of developing and supporting our cloud-based content and software; and fair value adjustments to acquisition-related earn-out liabilities.


•	Member relations and marketing expense includes the costs of acquiring new members and the costs of account management, and consists of compensation (including sales incentives); travel and entertainment expenses; costs for training personnel; sales and marketing materials; and associated support services.


•	General and administrative expense includes the costs of human resources and recruiting; finance and accounting; legal support; management information systems; real estate and facilities management; corporate development; new program development; and other administrative functions.


•	Depreciation and amortization expense includes the cost of depreciation of our property and equipment; amortization of costs associated with the development of software and tools that are offered as part of certain of our membership programs; and amortization of acquired intangibles.


•	Impairment of capitalized software includes the impairment charge taken to write down acquired technology and internally developed capitalized software balances to their fair value.


•	Goodwill impairment includes the impairment charge taken to write down goodwill to its estimated fair value.

Our operating costs for each period include stock-based compensation expenses and expenses representing additional payroll taxes for compensation expense as a result of the taxable income employees recognize upon their exercise of common stock options and the vesting of restricted stock units issued under our stock incentive plans.

Critical Accounting Policies

Our accounting policies, which are in compliance with U.S. generally accepted accounting principles, or “GAAP,” require us to apply methodologies, estimates, and judgments that have a significant effect on the results we report in our financial statements. In our 2016 Form 10-K, we have discussed those material accounting policies that we believe are critical and require the use of complex judgment in their application. There have been no material changes to our policies since our fiscal year ended December 31, 2016.

Non-GAAP Financial Presentation

This management’s discussion and analysis presents supplemental measures of our performance which are derived from our consolidated financial information but which are not presented in our consolidated financial statements prepared in accordance with ~~accounting principles generally accepted in the United States of America, or “~~GAAP.” These financial measures, which are considered “non-GAAP financial measures” under SEC rules, are referred to as adjusted revenue, adjusted EBITDA, adjusted net income, and non-GAAP earnings per diluted share. See “Non-GAAP Financial Measures” below for information about our use of these non-GAAP financial measures, including our reasons for including the measures, material limitations with respect to the usefulness of such measures, and reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure.

Table of Contents

Results of Operations

	Three Months Ended March 31,
	2017					2016
Revenue	$	194,539		100.0	%	$	200,735		100.0	%
Costs and expenses:
Cost of services, excluding depreciation and amortization	98,642			50.7	%	95,949			47.8	%
Member relations and marketing	32,855			16.9	%	32,395			16.1	%
General and administrative	39,088			20.1	%	31,828			15.9	%
Depreciation and amortization	22,334			11.5	%	19,767			9.8	%
Total costs and expenses	192,919			99.2	%	179,939			89.6	%
Operating income	1,620			0.8	%	20,796			10.4	%
Other expense:
Interest expense	(4,500		)	(2.3	)%	(4,821		)	(2.4	)%
Other income, net	233			0.1	%	61			—	%
Total other expense, net	(4,267		)	(2.2	)%	(4,760		)	(2.4	)%
(Loss) income before benefit (provision) for income taxes and gains (losses) from equity method investments	(2,647		)	(1.4	)%	16,036			8.0	%
Benefit (provision) for income taxes	724			0.4	%	(5,663		)	(2.8	)%
Gains (losses) from equity method investments	21,577			11.1	%	(34		)	—	%
Net income	$	19,654		10.1	%	$	10,339		5.2	%

Three months ended March 31, 2017 compared to the three months ended March 31, 2016

Net income. Net income increased to $19.7 million in the three months ended March 31, 2017 from $10.3 million in the three months ended March 31, 2016. The increase in net income was primarily attributable to a $23.4 million post-tax gain recorded in the three months ended March 31, 2017 on the exchange of Evolent Health LLC B units and Evolent Inc. Class B shares for Evolent Inc. Class A common stock and immediate sale of such shares. The effect of gain was offset by the increases in operating expenses related to our previously announced restructuring plan.

Revenue. Total revenue decreased 3.1% to $194.5 million in the three months ended March 31, 2017 from $200.7 million in the three months ended March 31, 2016, while adjusted contract value increased 1.5% to $756.2 million as of March 31, 2017 from $744.7 million as of March 31, 2016. The decreases in the three months ended March 31, 2017 were primarily the impact of the discontinuation of several programs, announced in conjunction with restructuring plan on January 3, 2017, and lower health care technology sales at the end of 2016, primarily as a result of uncertainty about health care policy under the new administration.

Cost of services. Cost of services increased to $98.6 million in the three months ended March 31, 2017 from $95.9 million in the three months ended March 31, 2016. As a percentage of revenue, cost of services was 50.7% and 47.8% in the three months ended March 31, 2017 and March 31, 2016, respectively. The increase in cost of services was attributable to an increase in exited programs costs related to our restructuring plan. Cost of services included fair value adjustments to our acquisition-related earn-out liabilities, which consisted of an increase of $0.4 million and a decrease of $1.1 million in the three months ended March 31, 2017 and 2016, respectively.

Member relations and marketing expense. Member relations and marketing expense increased to $32.9 million in the three months ended March 31, 2017 from $32.4 million in the three months ended March 31, 2016. The increase in member relations and marketing expense was primarily attributable to increases in sales staff and related travel and other associated costs, as well as to an increase in member relations personnel and related costs required to serve our expanding membership base. As a percentage of revenue, member relations and marketing expense was 16.9% and 16.1% in the three months ended March 31, 2017 and 2016, respectively.

General and administrative expense. General and administrative expense increased to $39.1 million in the three months ended March 31, 2017 from $31.8 million in the three months ended March 31, 2016. The increase in general and administrative expense in the current period was primarily attributable to increases in severance and other personnel costs of

Table of Contents

~~$6.7~~Results ~~million related to our restructuring plan. As a percentage~~ of ~~revenue, general and administrative expense increased to 20.1% in the three months ended March 31, 2017 from 15.9% in the three months ended March 31, 2016.~~Operations

~~Depreciation~~The ~~and~~following ~~amortization~~tables ~~expense.~~show ~~Depreciation~~consolidated ~~and~~statements ~~amortization~~of ~~expense~~operations ~~increased to $22.3 million in the three months ended March 31~~data, ~~2017~~including ~~from $19.8 million in~~ the ~~three~~amounts ~~months~~expressed ~~ended~~as ~~March 31, 2016. As~~ a percentage of revenue, ~~depreciation~~for ~~and~~the ~~amortization~~periods ~~expense~~indicated ~~was 11.5% and 9.8%~~ (in ~~the three months ended March 31~~thousands, ~~2017~~except and 2016, respectively. The increase in depreciation and amortization expense in the current period was primarily attributable to increased amortization expense from developed capitalized internal-use software and depreciation of improvements made to build-out new office space.percentages):

Interest expense. Interest expense decreased to $4.5 million for the three months ended March 31, 2017 from $4.8 million for the three months ended March 31, 2016. The decrease in interest expense was due to lower average debt balances as a result of scheduled principal payments under our term loan facility since the 2016 quarter.



	Three Months Ended June 30,
	2017					2016
Revenues:
Health care	$	133,669		66.7	%	$	142,387		71.8	%
Education	66,630			33.3	%	55,995			28.2	%
Total revenues	200,299			100.0	%	198,382			100.0	%
Costs and expenses:
Cost of services, excluding depreciation and amortization	101,788			50.8	%	96,440			48.6	%
Member relations and marketing	33,241			16.6	%	32,718			16.5	%
General and administrative	44,475			22.2	%	32,219			16.2	%
Depreciation and amortization	21,645			10.8	%	18,917			9.5	%
Total costs and expenses	201,149			100.4	%	180,294			90.8	%
Operating income	(850		)	(0.4	)%	18,088			9.2	%
Other expense:
Interest expense	(4,730		)	(2.4	)%	(4,389		)	(2.2	)%
Other expense, net	(90		)	—	%	(923		)	(0.5	)%
Total other expense, net	(4,820		)	(2.4	)%	(5,312		)	(2.7	)%
(Loss) income before benefit (provision) for income taxes and gains (losses) from equity method investments	(5,670		)	(2.8	)%	12,776			6.5	%
Benefit (provision) for income taxes	2,681			1.3	%	(4,870		)	(2.6	)%
Gains (losses) from equity method investments	17,736			8.9	%	(411		)	(0.2	)%
Net income	$	14,747		7.4	%	$	7,495		3.7	%

Other expense, net. Other expense, net was $0.2 million in the three months ended March 31, 2017 compared to $0.1 million in the three months ended March 31, 2016. We recognized foreign exchange gains of $0.2 million and $0.1 million in the three months ended March 31, 2017 and 2016, respectively, as a result of the effect of fluctuating currency rates on our receivable balances denominated in foreign currencies.

Benefit (provision) for income taxes. Our income tax benefit was $0.7 million for the three months ended March 31, 2017. Our provision for income taxes was $5.7 million for the three months ended March 31, 2016. Our effective tax rate for the three months ended March 31, 2017 was 27.4% compared to 35.3% for the three months ended March 31, 2016. The decrease in the current period tax rate was primarily due to our tax loss position combined with the new stock-based compensation guidance, see Note 2, "Recent accounting pronouncements", where differences between tax deductions generated and recognized compensation expense from stock option exercises and restricted stock vesting now flow through our tax rate, and a change in the our estimated Research and Development tax credit from $1.8 million to $3.5 million in the three months ended March 31, 2016 and 2017, respectively.

Deferred tax assets are reduced by a valuation allowance when, in our management’s opinion, it is more likely than not that some portion of the entire deferred tax asset will not be realized. As of March 31, 2017, there was no change in the realizability of the deferred tax assets.

Gains (losses) from equity method investments. Gains and losses from our investments in Evolent LLC and Evolent Inc., net of tax, was a gain of $21.6 million in the three months ended March 31, 2017 and a loss of $34 thousand in the three months ended March 31, 2016. The primary driver for the gain in the current period was recognition of a post-tax gain of $23.4 million on the exchange of Evolent Health LLC B units and Evolent Inc. Class B shares for Evolent Inc. Class A common stock and immediate sale of such shares during the three months ended March 31, 2017. Total cash received from the transaction was $41.4 million. Our results for the three months ended March 31, 2016 included a $2.0 million dilution gain and a $0.2 million tax benefit for the tax effects of current year losses received from Evolent LLC, offset by our allocated share of losses of $2.2 million.

Stock-based compensation expense. We recognized the following stock-based compensation expense in the consolidated statements of operations line items for stock options and restricted stock units, or "RSUs," issued under our stock incentive plans for the three months ended March 31, 2017 and 2016 (in thousands):

	Three Months Ended March 31,
	2017		2016
Stock-based compensation expense included in:
Costs and expenses:
Cost of services	$	1,258	$	2,187
Member relations and marketing	1,146		1,114
General and administrative	3,307		3,681
Total costs and expenses	$	5,711	$	6,982

There are no stock-based compensation costs capitalized as part of the cost of an asset.

As of March 31, 2017, $56.0 million of total unrecognized compensation cost related to outstanding options and non-vested RSUs was expected to be recognized over a weighted average period of 2.8 years.

Table of Contents

Restructuring. During the three months ended March 31, 2017, we approved a restructuring plan and a process to explore, review, and evaluate a range of potential strategic alternatives focused on maximizing shareholder value. In connection with our restructuring plan, we are reducing our workforce as a part of a broader effort to more closely align operating expenses with our long-term strategic initiatives and current macroeconomic business conditions. We anticipate that the reduction-in-force will affect approximately 220 employees and that it will be completed during fiscal year 2017. As of March 31, 2017, 112 positions have been eliminated. We will also be closing four offices and completing a gradual wind-down process of several healthcare products to be completed by the end of 2017.



	Six Months Ended June 30,
	2017					2016
Revenues:
Health care	$	265,852		67.3	%	$	288,229		72.2	%
Education	128,986			32.7	%	110,888			27.8	%
Total revenue	394,838			100.0	%	399,117			100.0	%
Costs and expenses:
Cost of services, excluding depreciation and amortization	200,430			50.8	%	192,389			48.2	%
Member relations and marketing	66,096			16.7	%	65,113			16.3	%
General and administrative	83,563			21.2	%	64,047			16.0	%
Depreciation and amortization	43,979			11.1	%	38,684			9.7	%
Total costs and expenses	394,068			99.8	%	360,233			90.2	%
Operating income	770			0.2	%	38,884			9.8	%
Other expense:
Interest expense	(9,230		)	(2.3	)%	(9,210		)	(2.3	)%
Other income (expense), net	143			—	%	(862		)	(0.2	)%
Total other expense, net	(9,087		)	(2.3	)%	(10,072		)	(2.5	)%
(Loss) income before benefit (provision) for income taxes and gains (losses) from equity method investments	(8,317		)	(2.1	)%	28,812			7.3	%
Benefit (provision) for income taxes	3,405			0.9	%	(10,533		)	(2.7	)%
Gains (losses) from equity method investments	39,313			10.0	%	(445		)	(0.1	)%
Net income	$	34,401		8.8	%	$	17,834		4.5	%

AsThree ~~a result of these actions, we incurred salary, severance,~~ and ~~other~~six ~~employee benefit costs of $7.3 million, legal and consulting fees of $2.9 million, and other operating costs of $1.0 million during the three~~ months ended ~~March~~June 3130, 2017. ~~These~~compared ~~costs~~to ~~were recognized in cost of services, member relations and marketing, and general and administrative on~~ the ~~accompanying~~three ~~statements of operations in the amounts of $2.3 million, $0.3 million,~~ and ~~$8.6~~six ~~million, respectively. No material lease exit costs were incurred during the three~~ months ended ~~March~~June 3130, 2017 and there are no material accruals recorded on the consolidated balance sheet as of March 31, 2017 related to the restructuring plan. We expect to recognize approximately $37.5 million of additional restructuring and strategic plan related costs during the remainder of fiscal year 2017. No restructuring or exit costs were incurred in the three months ended March 31, 2016.

Net income. Net income increased to $14.7 million in the three months ended June 30, 2017 from $7.5 million in the three months ended June 30, 2016, and increased to $34.4 million in the six months ended June 30, 2017 from $17.8 million in the six months ended June 30, 2016. The increases in net income in the current periods were primarily attributable to post-tax gains of $18.9 million and $42.3 million recorded in the three months and the six months ended June 30, 2017, respectively, on one sale in the three months ended and two sales in the six months ended of shares of Class A common stock of Evolent Health Inc., or "Evolent Inc.," received in exchange, on a one-for-one basis, for Class B common units of Evolent Health LLC, or "Evolent LLC," and shares of Evolent Inc. Class B common stock. The effect of the gains was offset by increases in operating expenses related to our previously announced restructuring plan.

Revenue. Total revenue increased 1.0% to $200.3 million in the three months ended June 30, 2017 from $198.4 million in the three months ended June 30, 2016. Total revenue decreased 1.1% to $394.8 million in the six months ended June 30, 2017 from $399.1 million in the six months ended June 30, 2016, while adjusted contract value decreased 4.4% to $723.2 million as of June 30, 2017 from $756.6 million as of June 30, 2016.

Revenue from our health care business decreased 6.1% to $133.7 million in the three months ended June 30, 2017 from $142.4 million in the three months ended June 30, 2016, and decreased 7.7% to $265.9 million in the six months ended June 30, 2017 from $288.2 million in the six months ended June 30, 2016. The decreases in the three and six months ended June 30, 2017 were primarily due to the discontinuation of several programs, announced in conjunction with our restructuring plan on January 3, 2017, and lower health care technology sales at the end of 2016, primarily as a result of uncertainty about health care policy under the new Presidential administration.

Revenue from our education business increased 18.9% to $66.6 million in the three months ended June 30, 2017 from $56.0 million in the three months ended June 30, 2016, and increased 16.3% to $129.0 million in the six months ended June 30, 2017 from $110.9 million in the six months ended June 30, 2016. The increases in the three and six months ended June 30, 2017 were primarily due to strong renewal rates in our data-enabled services programs and an increase in market penetration for our performance technology programs.

Cost of services. Cost of services increased to $101.8 million in the three months ended June 30, 2017 from $96.4 million in the three months ended June 30, 2016, and increased to $200.4 million in the six months ended June 30, 2017 from $192.4 million in the six months ended June 30, 2016. As a percentage of revenue, cost of services was 50.8% and 48.6% in

Table of Contents

the three months ended June 30, 2017 and 2016, respectively, and 50.8% and 48.2% in the six months ended June 30, 2017 and 2016. The increase in cost of services was attributable to an increase in exited program costs related to our restructuring plan of $2.9 million and $5.4 million in the three and six months ended June 30, 2017, respectively. Cost of services included fair value adjustments to our acquisition-related earn-out liabilities, which consisted of an increase of $0.1 million and $1.8 million in the three months ended June 30, 2017 and 2016, respectively, and an increase of $0.5 million and $0.7 million in the six months ended June 30, 2017 and 2016, respectively.

Member relations and marketing expense. Member relations and marketing expense increased to $33.2 million in the three months ended June 30, 2017 from $32.7 million in the three months ended June 30, 2016, and increased to $66.1 million in the six months ended June 30, 2017 from $65.1 million in the six months ended June 30, 2016. The increase in member relations and marketing expense was primarily attributable to increases in sales staff and related travel and other associated costs, as well as to an increase in member relations personnel and related costs required to serve our expanding membership base. As a percentage of revenue, member relations and marketing expense was 16.6% and 16.5% in the three months ended June 30, 2017 and 2016, respectively, and 16.7% and 16.3% in the six months ended June 30, 2017 and 2016, respectively.

General and administrative expense. General and administrative expense increased to $44.5 million in the three months ended June 30, 2017 from $32.2 million in the three months ended June 30, 2016, and increased to $83.6 million in the six months ended June 30, 2017 from $64.0 million in the six months ended June 30, 2016. The increases in general and administrative expense were primarily attributable to additional costs related to our restructuring and strategic alternatives plan of $12.2 million and $20.7 million in the three and six months ended June 30, 2017, respectively. As a percentage of revenue, general and administrative expense increased to 22.2% in the three months ended June 30, 2017 from 16.2% in the three months ended June 30, 2016, and increased to 21.2% in the six months ended June 30, 2017 from 16.0% in the six months ended June 30, 2016.

Depreciation and amortization expense. Depreciation and amortization expense increased to $21.6 million in the three months ended June 30, 2017 from $18.9 million in the three months ended June 30, 2016, and increased to $44.0 million in the six months ended June 30, 2017 from $38.7 million in the six months ended June 30, 2016. The increases in depreciation and amortization expense in the current periods were primarily attributable to increased amortization expense from developed capitalized internal-use software, depreciation of improvements made to build out new office space, and a $0.7 million loss on the disposal of furniture, fixtures, and equipment. As a percentage of revenue, depreciation and amortization expense increased to 10.8% in the three months ended June 30, 2017 from 9.5% in the three months ended June 30, 2016, and increased to 11.1% in the six months ended June 30, 2017 from 9.7% in the six months ended June 30, 2016.

Interest expense. Interest expense increased to $4.7 million for the three months ended June 30, 2017 from $4.4 million for the three months ended June 30, 2016, and was consistent at $9.2 million in the six months ended June 30, 2017 and 2016. The increase in interest expense during the three months ended June 30, 2017 compared to the prior period was due to an increase in the stated annual interest rate, the London interbank offered rate plus a 2.00% interest rate margin, on our outstanding credit facility borrowings during the current period.

Other expense, net. Other expense, net was expense $0.1 million in the three months ended June 30, 2017 compared to expense of $0.9 million in the three months ended June 30, 2016, and income of $0.1 million in the six months ended June 30, 2017 compared to expense of $0.9 million in the six months ended June 30, 2016. We recognized foreign exchange expense of $0.1 million and $0.8 million in the three months ended June 30, 2017 and 2016, respectively, and income of $0.1 million and expense of $0.7 million in the six months ended June 30, 2017 and 2016, respectively, as a result of the effect of fluctuating currency rates on our receivable balances denominated in foreign currencies.

Benefit (provision) for income taxes. Our income tax benefit was $2.7 million for the three months ended June 30, 2017 and our provision for income taxes was $4.9 million for the three months ended June 30, 2016. Our income tax benefit was $3.4 million for the six months ended June 30, 2017 and our provision for income taxes was $10.5 million for the six months ended June 30, 2016. Our effective tax rate for the three months ended June 30, 2017 was 47.3% compared to 38.1% for the three months ended June 30, 2016. Our effective tax rate for the six months ended June 30, 2017 was 40.9% compared to 36.6% for the six months ended June 30, 2016. The increase in the current period tax rate was primarily due to our tax loss position as compared to income positions in the comparative periods of 2016.

Deferred tax assets are reduced by a valuation allowance when, in our management’s opinion, it is more likely than not that some portion of the entire deferred tax asset will not be realized. As of June 30, 2017, there was no change in the realizability of the deferred tax assets.

Gains (losses) from equity method investments. Gains and losses from our investments in Evolent LLC and Evolent Inc., net of tax, was a gain of $17.7 million in the three months ended June 30, 2017 and a loss of $0.4 million in the three months ended June 30, 2016. Gains and losses from our investments in Evolent LLC and Evolent Inc., net of tax, was a gain of $39.3 million in the six months ended June 30, 2017 and a loss of $0.4 million in the six months ended June 30, 2016. The

Table of Contents

primary driver for the gain in the current periods was recognition of post-tax gains of $18.9 million and $42.3 million for the three and six months ended June 30, 2017, respectively, on sales of shares of Evolent Inc. Class A common stock we received in exchange, on a one-for-one basis, for Evolent LLC Class B common units and shares of Evolent Inc. Class B common stock. Our proportionate share of losses in our investments in Evolent LLC and Evolent Inc. was $1.8 million and $4.7 million during the three and six months ended June 30, 2017, respectively. The Company had no unrecorded losses related to its investment in Evolent LLC and Evolent Inc. as of June 30, 2017. During the three and six months ended June 30, 2016, our proportionate share of losses in our investments in Evolent Inc. and Evolent LLC were $2.2 million and $4.5 million, respectively, of which $0.5 million and $2.7 million, respectively, was recognized in our consolidated statements of operations. These losses were offset by a dilution gain of $2.0 million during the six months ended June 30, 2016. We had a total of $1.7 million in unrecorded losses related to our investments in Evolent Inc. and Evolent LLC as of June 30, 2016.

Stock-based compensation expense. We recognized the following stock-based compensation expense in the consolidated statements of operations line items for stock options and restricted stock units, or "RSUs," issued under our stock incentive plans for the three and six months ended June 30, 2017 and 2016 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Stock-based compensation expense included in:
Costs and expenses:
Cost of services	$	1,829	$	2,493	$	3,087	$	4,680
Member relations and marketing	1,134		1,387		2,280		2,501
General and administrative	2,651		4,085		5,958		7,766
Total costs and expenses	$	5,614	$	7,965	$	11,325	$	14,947

There are no stock-based compensation costs capitalized as part of the cost of an asset.

As of June 30, 2017, $49.2 million of total unrecognized compensation cost related to outstanding options and non-vested RSUs was expected to be recognized over a weighted average period of 2.5 years.

Restructuring and strategic alternative costs. During 2017, we approved a restructuring plan and a process to explore, review, and evaluate a range of potential strategic alternatives focused on maximizing shareholder value. In connection with our restructuring and strategic alternatives plan, we are reducing our workforce as a part of a broader effort to more closely align operating expenses with our long-term strategic initiatives and current macroeconomic business conditions. We anticipate that the reduction-in-force will affect approximately 160 employees and will be completed during fiscal year 2017. As of June 30, 2017, 134 positions have been eliminated. We closed four offices and are completing a gradual wind-down process of several health care products, to be completed by the end of fiscal year 2017.

As a result of these actions, for the three and six months ended June 30, 2017, we incurred salary, severance, and other employee benefit costs of $5.0 million and $13.4 million, respectively, legal and financial advisory fees of $6.7 million and $9.5 million, respectively, and other operating costs, inclusive of primarily rent, depreciation, and contract exit costs, of $8.3 million and $12.8 million, respectively. For the three and six months ended June 30, 2017, we recognized in our consolidated statement of operations $4.5 million and $10.1 million, respectively, of such amounts in cost of services; $0.1 million and $0.4 million, respectively, of such amounts in member relations and marketing expense; $12.8 million and $21.4 million, respectively, of such amounts in general and administrative expense; and $2.6 million and $3.8 million, respectively, of such amounts in depreciation and amortization expense. We incurred lease exit costs of $3.2 million during both the three and six months ended June 30, 2017. No restructuring or exit costs were incurred in the three and six months ended June 30, 2016.

Non-GAAP Financial Measures

The tables below present supplemental measures of our performance which we have derived from our consolidated financial information but which are not presented in our consolidated financial statements prepared in accordance with GAAP. We refer to these financial measures, which are considered “non-GAAP financial measures” under SEC rules, as adjusted revenue, adjusted EBITDA, adjusted net income, and non-GAAP earnings per diluted share.

Our management uses these non-GAAP financial measures, together with financial measures prepared in accordance with GAAP, to enhance understanding by investors of our core operating performance, as well as for internal forecasting purposes. Our management believes that providing information about these non-GAAP financial measures facilitates an assessment by our investors of our fundamental operating trends and addresses concerns of investors that various financing, acquisition-related, non-cash, and other effects included in GAAP measures may obscure such underlying trends. We believe that, by highlighting such trends relating to our underlying performance, our non-GAAP presentation helps our investors to make meaningful period-to-period comparisons of our results.

Table of Contents

our investors of our fundamental operating trends and addresses concerns of investors that various financing, acquisition-related, non-cash, and other effects included in GAAP measures may obscure such underlying trends. We believe that, by highlighting such trends relating to our underlying performance, our non-GAAP presentation helps our investors to make meaningful period-to-period comparisons of our results.

There are limitations to the use of our non-GAAP financial measures. These non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Our non-GAAP financial measures exclude the items discussed below. Because the excluded items have a material impact on our financial results, we use non-GAAP financial measures to supplement financial information presented in accordance with GAAP.

Reconciliations of each non-GAAP financial measure to its most directly comparable GAAP financial measure are set forth below. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. The discussion below presents information about each of the non-GAAP financial measures and our reasons for excluding the enumerated items from our non-GAAP results. In future fiscal periods, we may exclude such items and may incur income and expenses similar to these excluded items. Accordingly, the exclusion of these items and other similar items in our non-GAAP presentation should not be interpreted as implying that these items are non-recurring, infrequent, or unusual.

Adjusted Revenue

We adjust revenue to exclude the impact of exited programs. Our management believes that the adjustments for these items more closely correlate the reported financial measure with the ordinary and ongoing course of our operations.

Adjusted Net Income and Non-GAAP Earnings Per Diluted Share

We present adjusted net income and non-GAAP earnings per diluted share to provide investors with a meaningful, consistent comparison of our operating results and trends for the periods presented. Our management believes that these measures are also useful to investors by allowing investors to evaluate our operations using the same tools that management uses to evaluate our past performance and prospects for future performance. These two non-GAAP financial measures reflect adjustments based on the exclusion of the following items as well as adjustments for related income tax effects:

24• Losses (income) from exited programs: We have excluded income (loss) from exited programs. These include revenue and direct costs, including salary and benefits. We believe that the exclusion of such amounts allows investors to better understand our core continuing operations.

Table of Contents

• Losses (income) from exited programs: We have excluded income (loss) from exited programs. These include revenue and direct costs, including salary and benefits. We believe that the exclusion of such amounts allows investors to better understand out core continuing operations.


•	Gain (loss) from equity method investments: We have excluded our proportionate share of income (loss) and other gains recorded in connection with our equity method investments. Our management believes that the exclusion of such amounts allows investors to better understand our core operating results.

•

Amortization of acquisition-related intangible assets: Amortization of acquisition-related intangible assets consists of amortization of customer relationships, developed technology, and trade names. Amortization charges for acquired intangible assets are significantly affected by the timing and magnitude of our acquisitions, and these charges may vary in amount from period to period. We exclude these charges to facilitate a more meaningful evaluation of our current operating performance and comparisons to our past operating performance.

•

Fair value adjustments to acquisition-related earn-out liabilities: We have excluded the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates. The amount and frequency of such adjustments are not consistent across transactions and are significantly affected by the timing and size of our acquisitions, the future outlook of the acquired business, the estimated discount rate, and the nature of the transaction consideration.

•

Build-to-suit land rent: We entered into a 16-year lease for our new corporate headquarters in December 2015, which is currently being constructed in Washington D.C. The lease has an anticipated start date of mid-2019. We have concluded that we are the deemed owner of the building (for accounting purposes only) during the construction period and that the lease qualifies for build-to-suit accounting. We recognize expense on a portion of future lease payments that are estimated to represent the underlying land lease. We exclude these costs for purposes of calculating non-GAAP measures because we believe these costs do not reflect expected future operating expenses and do not contribute to a meaningful evaluation of our current operating performance or comparisons to our operating performance in other periods.

Table of Contents

•

Stock-based compensation expense: Although stock-based compensation is a key incentive offered to our employees, we evaluate our operating results excluding such expense because the expense can vary significantly from period to period based on our share price, as well as the timing, size, and nature of equity awards granted. In addition, our management believes that the exclusion of this expense facilitates the ability of our investors to compare our operating results with those of other companies, many of which also exclude such expense in determining their non-GAAP financial measures.

• Restructuring and strategic alternative charges: We have excluded costs associated with our ~~formal~~previously announced restructuring plan ~~announced~~and onour ~~January~~work 3,on ~~2017~~strategic alternatives. These costs of our restructuring and strategic alternatives plan are primarily related to employee termination costs and benefits, ~~and~~lease exit costs, toand ~~terminate~~legal ~~leases~~and financial advisory fees. We exclude these restructuring and strategic alternative costs for purposes of calculating non-GAAP measures because we believe that these ~~historical~~ costs do not reflect expected future operating expenses and do not contribute to a meaningful evaluation of our current operating performance or comparisons to our operating performance in other periods.

Adjusted EBITDA

Adjusted EBITDA reflects the adjustments to net income prepared on a GAAP basis, as discussed above, and, to the extent not already subject to such adjustments, excludes expenses related to interest, taxes, depreciation and amortization. Companies exhibit significant variations with respect to capital structure and cost of capital (which affects relative interest expense) and differences in taxation and book depreciation of facilities and equipment (which affect relative depreciation expense), including significant differences in the depreciable lives of similar assets among various companies. By eliminating some of these variations and reflecting the other adjustments, discussed above, our management believes that this non-GAAP financial measure allows investors to evaluate more effectively our fundamental operating performance relative to that of other companies.

Adjusted ~~net~~Effective ~~income~~Tax and adjusted EBITDA. Adjusted net income increased 3.2% to $19.2 million for the three months ended March 31, 2017 from $18.6 million for the three months ended March 31, 2016, and adjusted EBITDA decreased 2.0% to $45.0 million for the three months ended March 31, 2017 from $45.9 million for the three months ended March 31, 2016. Adjusted EBITDA decreased slightly and adjusted net income remained consistent for the three month period compared to the prior year. This is attributable to lower health care technology sales at the end of 2016 as a result of uncertainty about health care policy under the new administration and increases in revenue and operating costs in our education business as a result of our continued investment in the business. Rate

25Adjusted effective tax rate is the effective tax rate prepared on a GAAP basis adjusted to exclude the effects of a rate change on our investments in Evolent Inc. and Evolent LLC during the three and six months ended June 30, 2017. We exclude these items because our management believes this non-GAAP financial measure will facilitate the comparison by investors of our annual effective tax rates over time. The adjusted effective tax rate is calculated by dividing the adjusted provision for income taxes, which excludes specified items, by the adjusted income before the provision for income taxes.

Adjusted net income and adjusted EBITDA. Adjusted net income decreased 18.7% to $15.3 million from $18.8 million for the three months ended June 30, 2017 and June 30, 2016, respectively, and adjusted EBITDA decreased 6.2% to $44.3 million from $47.2 million for the three months ended June 30, 2017 and June 30, 2016, respectively. Adjusted net income decreased 7.8% to $34.5 million from $37.4 million for the six months ended June 30, 2017 and June 30, 2016, respectively, and adjusted EBITDA decreased 4.1% to $89.3 million from $93.1 million for the six months ended June 30, 2017 and June 30, 2016, respectively. The decreases in adjusted net income and in adjusted EBITDA compared to the prior year periods were primarily attributable to increased costs related to new consulting arrangements, decreased capitalization of software development costs, and increased expense from third-party finance and accounting advisory services.



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Revenue	$	200,299	$	198,382	$	394,838	$	399,117
Revenue from exited programs	485		4,711		967		9,989
Adjusted revenue	$	199,814	$	193,671	$	393,871	$	389,128

Table of Contents

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Revenue	$	194,539		$	200,735
Net income	$	14,747		$	7,495		$	34,401		$	17,834
Revenue from exited programs	482			5,278
Loss (income) from exited programs	3,835			(48		)	7,884			(1,036		)
Adjusted revenue	$	194,057		$	195,457
Depreciation and amortization	21,645			18,917			43,979			38,684
Depreciation and amortization from exited programs	(1,872		)	(506		)	(3,110		)	(975		)
(Gains) losses from equity method investments	(17,736		)	411			(39,313		)	445
(Benefit) provision for income taxes	(2,681		)	4,870			(3,405		)	10,533
Interest expense	4,730			4,389			9,230			9,210
Other expense (income), net	90			923			(143		)	862
Fair value adjustments to acquisition-related earn-out liabilities	52			1,775			452			705
Build-to-suit land rent	931			995			1,862			1,871
Stock-based compensation expense	5,614			7,965			11,325			14,947
Restructuring and strategic alternative charges	14,915			—			26,128			—
Adjusted EBITDA	$	44,270		$	47,186		$	89,290		$	93,080

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Net income	$	1914,~~654~~747		$	107,~~339~~495		$	34,401		$	17,834
Loss (income) from exited programs	43,~~049~~835			(~~988~~48		)	7,884			(1,036		)
Depreciation and amortization	22,334			19,767
(Gains) losses from equity method investments	(17,736		)	411			(39,313		)	445
Depreciation and amortization from exited programs	(1,238		)	(469		)
Amortization of acquisition-related intangibles	6,593			6,975			13,400			14,013
(Gain) loss from equity method investments	(21,577		)	34
Fair value adjustments to acquisition-related earn-out liabilities	52			1,775			452			705
(Benefit) provision for income taxes	(724		)	5,663
Build-to-suit land rent	931			995			1,862			1,871
Interest expense	4,500			4,821
Stock-based compensation expense	5,614			7,965			11,325			14,947
Other expense, net	(233		)	(61		)
Restructuring and strategic alternative charges	14,915			—			26,128			—
Fair value adjustments to acquisition-related earn-out liabilities	400			(1,070		)
Income tax effects and adjustments	(13,634		)	(6,732		)	(21,596		)	(11,331		)
Build-to-suit land rent	931			876
Adjusted net income	$	15,317		$	18,836		$	34,543		$	37,448
Stock-based compensation expense	5,711			6,982
Restructuring charges	11,213			—
Adjusted EBITDA	$	45,020		$	45,894

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Net income	$	19,654		$	10,339
Net income per diluted share	$	0.36		$	0.18		$	0.83		$	0.43
Loss (income) from exited programs	~~4,049~~0.09			~~(988~~—		)	0.19			(0.03		)
(Gain) loss from equity method investments	(21,577		)	34
(Gains) losses from equity method investments	(0.43		)	0.01			(0.95		)	0.01
Amortization of acquisition-related intangibles	~~6,807~~0.16			~~7,038~~0.17			0.32			0.34
Fair value adjustments to acquisition-related earn-out liabilities	~~400~~—			~~(1,070~~0.04		)	0.01			0.02
Build-to-suit land rent	~~931~~0.02			~~876~~0.03			0.05			0.05
Stock-based compensation expense	~~5,711~~0.14			~~6,982~~0.20			0.28			0.36
Restructuring charges	11,213			—
Restructuring and strategic alternative charges	0.36			—			0.63			—
Income tax effects and adjustments	(~~7,962~~0.33		)	(~~4,599~~0.17		)	(0.52		)	(0.27		)
Adjusted net income	$	19,226		$	18,612
Non-GAAP adjusted earnings per diluted share	$	0.37		$	0.46		$	0.84		$	0.91

2629

Table of Contents

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016	~~2016~~		2017		2016
Net income per diluted share	$	0.48			$	0.25
Effective tax rate	47.3	%		38.1	%		40.9	%	36.6	%
Loss (income) from exited programs	0.10				(0.02		)
Effects of rate change on investments in Evolent Inc. and Evolent LLC	(4.6	)%		—	%		(3.1	)%	—	%
(Gain) loss from equity method investments	(0.53		)		—
Adjusted effective tax rate	42.7	%		38.1	%		37.8	%	36.6	%
Amortization of acquisition-related intangibles	0.17				0.17
Fair value adjustments to acquisition-related earn-out liabilities	0.01				(0.03		)
Build-to-suit land rent	0.02				0.02
Stock-based compensation expense	0.14				0.17
Restructuring charges	0.27				—
Income tax effects and adjustments	(0.19		)		(0.12		)
Non-GAAP adjusted earnings per diluted share	$	0.47			$	0.44

Liquidity and Capital Resources

Cash flows generated from operating activities represent our primary source of liquidity. We believe that operating cash flows and existing cash and cash equivalents will be sufficient to support our expected operating and capital expenditures, as well as debt service obligations, during at least the next 12 months.

Our cash and cash equivalents as of ~~March~~June 3130, 2017 increased to $~~150~~144.10 million from $91.2 million as of December 31, 2016. During the ~~three~~six months ended ~~March 31~~June 30, 2017, we received net cash proceeds of $4171.49 million from ~~the~~our ~~exchange~~sales of Evolent ~~Health LLC B units and Evolent~~ Inc. Class ~~B shares for Evolent Inc. Class~~ A common stock ~~and~~described ~~immediate~~elsewhere ~~sale~~in ofthis ~~such~~management's ~~shares~~discussion and analysis. We did not ~~purchase~~sell shares of ~~our~~Evolent ~~common~~Inc. ~~stock~~Class ~~through~~A ~~our~~common ~~share~~stock ~~repurchase program~~ during the ~~three~~six months ended ~~March~~June 3130, ~~2017. During the three months ended March 31,~~ 2016~~, we expended $27~~.4 ~~million in cash to purchase shares of our common stock through our share repurchase program.~~

We did not purchase shares of our common stock through our share repurchase program during the six months ended June 30, 2017. During the six months ended June 30, 2016, we expended $53.6 million in cash to purchase shares of our common stock through our share repurchase program.

Cash flows

Cash flows from operating activities. The combination of profitable operations and payment for services in advance of accrual revenue typically results in operating activities that generate cash flows in excess of net income on an annual basis. Cash flows from operating activities fluctuate from quarter to quarter based on the timing of new and renewal contracts as well as certain expenses. Net cash flows provided by operating activities ~~increased~~decreased to $2817.79 million in the ~~three~~six months ended ~~March~~June 3130, 2017 from net cash flows provided by operating activities of $2723.21 million in the ~~three~~six months ended ~~March~~June 3130, 2016. The ~~increase~~decrease in net cash flows provided by operating activities in the current period was primarily attributable to ~~improved~~ cash ~~collections~~outflows inof ~~the~~$23.9 ~~current~~million ~~period~~related asto ~~compared~~our torestructuring ~~prior~~and ~~period.~~strategic Inalternatives ~~addition~~plan, wethe ~~had~~effect ~~cash outflows~~ of ~~$10.1~~which ~~million~~was ~~during~~partially ~~the~~offset ~~three~~by ~~months~~improved ~~ended~~cash ~~March 31, 2017 related to the restructuring plan~~collections.

Cash flows from investing activities. Our cash management and investment strategy and capital expenditure programs affect investing cash flows. Net cash flows provided by investing activities was $3254.73 million in the ~~three~~six months ended ~~March~~June 3130, 2017 compared to net cash flows used in investing activities of $1223.4 million in the ~~three~~six months ended ~~March~~June 3130, 2016. The increase in net cash flows provided by investing activities during the current period was primarily attributable to cash ~~received~~of on$71.9 ~~the~~million ~~partial~~received ~~sale~~from of our ~~equity~~sales ~~method~~of ~~investment~~Evolent ~~$41~~Inc.4 ~~million~~Class A common stock, which was offset in part by payments of $817.76 million for capital expenditures. Investing activities during the ~~three~~six months ended ~~March~~June 3130, 2016 consisted of payments of $1.9 million for acquisitions and capital expenditures of $1021.5 million.

Cash flows from financing activities. We had net cash flows used in financing activities of $219.4 million and $3454.20 million in the ~~three~~six months ended ~~March~~June 3130, 2017 and 2016, respectively. Cash flows from financing activities during the ~~three~~six months ended ~~March~~June 3130, 2017 consisted of $721.26 million of debt repayments, the withholding of $05.82 million ofin shares to satisfy the minimum employee tax withholding for vested RSUs, and the payment of $0.2 million of acquisition-related earn-out payments. These cash flows were offset in part by $5.7.4 million of proceeds from the issuance of common stock upon the exercise of stock options.

Financing activities during the ~~three~~six months ended ~~March~~June 3130, 2016 primarily consisted of the repurchase of $2753.46 million of shares under our stock repurchase program, $714.24 million of debt repayments, a $3.6 million acquisition-related earn-out payment, and the withholding of $03.4 million of shares to satisfy the minimum employee tax withholding for vested RSUs. These cash flows were offset in part by $317.0 million of proceeds from borrowings under our revolving credit facility, $3.1 million of proceeds from the issuance of common stock upon the exercise of stock options and $10.36 million in additional tax benefits related to stock-based compensation arrangements.

Table of Contents

Senior secured credit facilities

On February 6, 2015, we obtained $675 million of senior secured credit facilities, referred to as the “credit facilities,” under a credit agreement with a syndicate of lenders. The credit facilities were amended on October 30, 2015.

Table of Contents

The amended credit facilities consist of (a) a five-year senior secured term loan facility in the principal amount of $475 million, or “term facility,” and (b) a five-year senior secured revolving credit facility, or “revolving credit facility,” under which up to $200 million principal amount of borrowings and other credit extensions may be outstanding at any time.

Term facility. The term loans are repayable in quarterly installments, which commenced with the quarter ended June 30, 2015, equal to a specified percentage of the aggregate principal amount drawn on the facility closing date, as follows: (a) 1.25% for each of the first eight full fiscal quarters following the facility closing date; (b) 2.50% for each of the ninth through twelfth full fiscal quarters following the facility closing date; and (c) 3.75% for each of the thirteenth through nineteenth full fiscal quarters following the facility closing date. As of ~~March~~June 3130, 2017, $~~417~~403.51 million was outstanding under the term facility.

Amounts drawn under the term facility generally bear interest, payable monthly, at an annual rate calculated, at our option, on the basis of either (a) an alternate base rate plus an initial margin of 1.25% or (b) the applicable London interbank offered rate, or “LIBOR,” plus an initial margin of 2.25%, subject in each case to margin reductions based on our total leverage ratio from time to time. As of ~~March~~June 3130, 2017, based on our historical leverage ratio, the interest rate margin was 2.00%. ~~For the three months ended March 31, 2017, borrowings under this facility accrued interest at a weighted average rate of 2.99%.~~

Revolving credit facility. As of ~~March~~June 3130, 2017, under the revolving credit facility, $100 million of borrowings were outstanding, $19.1 million of standby letters of credit had been issued, and $80.9 million was available for future borrowings.

Amounts drawn under the revolving credit facility generally bear interest, payable quarterly, at an annual rate calculated, at our option, on the basis of either (a) an alternate base rate plus an initial margin of 1.25% or (b) the applicable London interbank offered rate plus an initial margin of 2.25%, subject in each case to margin reductions based on our total leverage ratio from time to time. As of ~~March~~June 3130, 2017, based on our historical leverage ratio, the interest rate margin was 2.00%. ~~For the three months ended March 31, 2017, borrowings under this facility accrued interest at a weighted average rate of 2.99%.~~

We are obligated to pay a commitment fee at an initial annual rate of 0.25%, subject to reduction based on our total leverage ratio from time to time, accruing on the average daily amount of available commitments under the revolving credit facility.

We are required to maintain compliance with financial covenants consisting of (a) a maximum total leverage ratio and (b) a minimum interest coverage ratio, each measured as of the last day of our fiscal quarter, for a period consisting of our most recently completed four fiscal quarters. We were in compliance with these financial covenants as of ~~March~~June 3130, 2017.

Contractual Obligations

There were no material changes related to contractual obligations and commitments from the information provided in our 2016 Form 10-K.

Off-Balance Sheet Arrangements

As of ~~March~~June 3130, 2017, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition or results of operations.

Seasonality

Our revenues and operating results normally fluctuate as a result of seasonal variations in our business, principally due to certain education program offerings in which contracts typically are aligned with our members' academic year. Historically, these education programs have had lower revenues in the second and third calendar quarters and higher revenues in the first and fourth calendar quarters. We expect quarterly fluctuations in operating results to continue as a result of seasonal patterns. Such patterns may change, however, as a result of changes in service, timing, contract terms, new program offerings, increased sales, or acquisitions.

2831

Table of Contents



Item 3.	Quantitative and Qualitative Disclosures About Market Risk.

Interest rate risk. As of ~~March~~June 3130, 2017, we had $~~417~~403.51 million of outstanding borrowings under our term facility and $100.0 million of outstanding borrowings under our revolving credit facility. Amounts drawn under each facility generally bear interest, payable quarterly, at an annual rate calculated, at our option, on the basis of either (a) an alternate base rate plus an initial margin of 1.25% or (b) the applicable London interbank offered rate, plus an initial margin of 2.25%, subject in each case to margin reductions based on our total leverage ratio from time to time. As of ~~March~~June 3130, 2017, our outstanding borrowings accrued interest at an annual rate of 23.9923%. Accordingly, we are exposed to fluctuations in interest rates on borrowings under the facilities. A hypothetical 10% increase in LIBOR would increase our annual cash interest expense on our variable-rate debt by approximately $0.56 million.

We utilize three interest rate swaps to manage our exposure to changes in interest rates on a portion of ~~the~~our variable -rate ~~of our~~ indebtedness. Our interest rate swaps are with major financial institutions and are not used for speculative or trading purposes. As of ~~March~~June 3130, 2017, the outstanding notional amount on the interest rate swaps was $~~258~~251.86 million. Our objective with respect to these interest rate swaps is to protect us against adverse fluctuations in interest rates by reducing our exposure to variability in cash flows relating to interest payments on a portion of our outstanding debt. We have designated our interest rate swaps as cash flow hedges, and changes in the fair value of the interest rate swaps are recognized in other comprehensive income (loss) in our consolidated statements of operations appearing elsewhere in this report. Hedge ineffectiveness, if any, associated with the interest rate swap will be reported in interest expense. We have recorded the interest rate swaps at fair value, which amounted to an asset of $1.86 million as of ~~March~~June 3130, 2017.

Foreign currency risk. Our international operations, which account for approximately 2.4% of our revenue, subject us to risks related to currency exchange fluctuations. Prices for our services sold to members located outside the United States are sometimes denominated in local currencies (primarily British Pound Sterling). As a consequence, increases in the value of the U.S. dollar against local currencies in countries where we have members would result in a foreign exchange loss recognized by us. We recognized foreign exchange ~~gains~~losses of $0.21 million and $0.18 million in the three months ended ~~March~~June 3130, 2017 and 2016, respectively, and a gain of $0.1 million and loss of $0.7 million in the six months ended June 30, 2017 and 2016, respectively, which are included in other expense, net in our consolidated statements of operations appearing elsewhere in this report. A hypothetical 10% change in foreign currency exchange rates would not have had a material effect on our financial position as of ~~March~~June 3130, 2017.

2932

Table of Contents



Item 4.	Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

As previously disclosed under “Item 9A - Controls and Procedures” in our Annual Report on Form 10-K for our fiscal year ended December 31, 2016, we concluded that our disclosure controls and procedures were not effective as of December 31, 2016 due to a material weakness, in our internal control over financial reporting described below. Based on the previously disclosed material weakness which we continue to work to remediate and view as an integral part of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that, as of ~~the three months ended March~~June 3130, 2017, our disclosure controls and procedures were not effective. In light of the weakness in internal control over financial reporting, prior to filing our Annual Report on Form 10-K for our fiscal year ended December 31, 2016, and prior to filing this Quarterly Report on Form 10-Q, we completed substantive procedures that have allowed us to conclude that, notwithstanding the material weaknesses in our internal control over financial reporting described below, the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with GAAP.

The material weakness in our internal control over financial reporting, which is described more fully in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, that continued to exist as of ~~March~~June 3130, 2017 relates to the material weakness in our tax controls. Although we have made improvements to such controls, we have concluded that the material weakness has not been remediated as of June 30, 2017. Specifically, we have concluded that the internal controls over the tax accounts have not been designed or do not operate at a sufficient level of precision to prevent or detect and correct a material misstatement. We identified errors in current and prior periods in the tax accounts that resulted from control deficiencies in the tax process. These errors were not material to the affected financial statements. However, we concluded that these control deficiencies in aggregate represent a material weakness as there is a reasonable possibility that the controls as ~~follows:~~currently operating would not prevent or detect and correct a material misstatement.

1. With respect to the material weakness in the tax controls, although we have made control improvements, we have concluded that the material weakness has not been remediated as of March 31, 2017. Specifically, we have concluded that the internal controls over the tax accounts have not been designed or do not operate at a sufficient level of precision to prevent or detect and correct a material misstatement. The Company identified errors in current and prior periods in the tax accounts that resulted from control deficiencies in the tax process. These errors were not material to the affected financial statements. However, the Company concluded that these control deficiencies in aggregate represent a material weakness as there is a reasonable possibility the controls as currently operating would not prevent or detect and correct a material misstatement.

Management's Remediation Initiatives

We are making progress toward achieving the effectiveness of our disclosure controls and procedures. Remediation generally requires making changes to how controls are designed and then adhering to those changes for a sufficient period of time to ensure that the effectiveness of those changes is demonstrated with an appropriate amount of consistency. We have assigned ~~certain~~some personnel to implement and monitor our short-term and long-term remediation plans and other personnel to oversee the necessary remedial changes to the overall design of our internal control environment and to address the root causes of our material weakness.

~~Our~~With ~~initiatives~~respect to the material weakness in our tax controls, ~~summarized~~we ~~below~~have made control improvements, ~~are~~including ~~intended~~expanded toprocedures ~~remediate~~over completeness and accuracy of data utilized in our ~~material~~tax ~~weaknesses~~provision and enhanced documentation of management review controls. We also plan to ~~continue~~add personnel with additional experience and technical capability to ~~enhance~~provide ~~our~~effective ~~internal~~oversight ~~control~~of ~~over~~our ~~financial~~tax ~~reporting~~function.

1. With respect to the material weakness in the tax controls, we have made control improvements, including expanded procedures over completeness and accuracy of data utilized in our tax provision and enhanced documentation of management review controls. The Company also plans to add resources with additional experience and technical capability to provide effective oversight of our tax function.

(b) Changes in Internal Control over Financial Reporting

We are taking actions to remediate the material weaknesses related to our internal control over financial reporting, as described above. However, our remediation efforts were not complete as of ~~March~~June 3130, 2017. Other than the changes disclosed above, there were no material changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15 and 15d-15 under the Exchange Act that occurred during the three months ended ~~March~~June 3130, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3033

Table of Contents

PART II. OTHER INFORMATION



Item 1.	Legal Proceedings.

After the end of the second quarter in 2017, on August 3, 2017, a purported class-action lawsuit was filed in the U.S. District Court for Southern District of New York naming as defendants the Company and two of its executive officers, one of whom is a director. In the complaint, the plaintiff alleges that the Company’s public statements about its business and operations between January 21, 2015 and February 23, 2016 contained material misstatements and omissions in violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder which artificially inflated the Company’s stock price. In addition to compensatory damages in an unspecified amount and attorneys’ fees, the action seeks such relief as the district court deems just and proper. The Company intends to vigorously defend this action.



Item 1A.	Risk Factors.

As discussed in this report, our actual results could differ materially from the expected results expressed or implied in our forward-looking statements. There have been no material changes in our risk factors from those described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. The risks described in that report are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or operating results.



Item 6.	Exhibits.

(a) Exhibits. The Company files herewith or incorporates by reference herein the exhibits identified below. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K under Commission File No. 000-33283.

3.2.1			Amendment to Amended and Restated Bylaws of the Company adopted March 13, 2017. Incorporated by reference to Exhibit 3.2.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
10.1			The Advisory Board Company Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on June 1, 2017.
3.2.2			Amended and Restated Bylaws of the Company as in effect on March 13, 2017. Incorporated by reference to Exhibit 3.2.2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
10.38*			The Advisory Board Company Senior Management Severance and Change of Control Plan. Incorporated by reference to Exhibit 10.38 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
12.1			Computation of Ratio of Earnings to Fixed Charges
31.1			Certification of the Chief Executive Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934, as amended
31.2			Certification of the Chief Financial Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934, as amended
32.1			Certifications pursuant to 18 U.S.C. Section 1350
101			XBRL (Extensible Business Reporting Language). The following materials from the Company’s Quarterly Report on Form 10-Q for the period ended ~~March~~June 3130, 2017, formatted in XBRL: (i) Consolidated Balance Sheets as of ~~March~~June 3130, 2017 (unaudited) and December 31, 2016, (ii) Unaudited Consolidated Statements of Operations for the Three and Six Months Ended ~~March~~June 3130, 2017 and 2016, (iii) Unaudited Consolidated Statements of Comprehensive Income for the Three and Six Months Ended ~~March~~June 3130, 2017 and 2016, (v) Unaudited Consolidated Statements of Cash Flows for the Three and Six Months Ended ~~March~~June 3130, 2017 and 2016, and (v) Notes to Unaudited Consolidated Financial Statements
*			Management contracts or compensation plans or arrangements in which directors or executive officers participate.

3134

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		~~THE ADVISORY BOARD COMPANY~~	THE ADVISORY BOARD COMPANY
Date: May 9, 2017		By:	/s/ Michael T. Kirshbaum
Date:	August 9, 2017		By:	/s/ Michael T. Kirshbaum
			~~Michael T. Kirshbaum~~	Michael T. Kirshbaum
			~~Chief Financial Officer and Treasurer(Duly Authorized Officer)~~	Chief Financial Officer and Treasurer(Duly Authorized Officer)

3235

Table of Contents

INDEX TO EXHIBITS

ExhibitNumber			Description of Exhibit
3.2.1			Amendment to Amended and Restated Bylaws of the Company adopted March 13, 2017. Incorporated by reference to Exhibit 3.2.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
10.1			The Advisory Board Company Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on June 1, 2017.
3.2.2			Amended and Restated Bylaws of the Company as in effect on March 13, 2017. Incorporated by reference to Exhibit 3.2.2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
10.38*			The Advisory Board Company Senior Management Severance and Change of Control Plan. Incorporated by reference to Exhibit 10.38 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
12.1			Computation of Ratio of Earnings to Fixed Charges
31.1			Certification of the Chief Executive Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934, as amended
31.2			Certification of the Chief Financial Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934, as amended
32.1			Certifications pursuant to 18 U.S.C. Section 1350
101			XBRL (Extensible Business Reporting Language). The following materials from the Company’s Quarterly Report on Form 10-Q for the period ended ~~March~~June 3130, 2017, formatted in XBRL: (i) Consolidated Balance Sheets as of ~~March~~June 3130, 2017 (unaudited) and December 31, 2016, (ii) Unaudited Consolidated Statements of Operations for the Three and Six Months Ended ~~March~~June 3130, 2017 and 2016, (iii) Unaudited Consolidated Statements of Comprehensive Income for the Three and Six Months Ended ~~March~~June 3130, 2017 and 2016, (v) Unaudited Consolidated Statements of Cash Flows for the Three and Six Months Ended ~~March~~June 3130, 2017 and 2016, and (v) Notes to Unaudited Consolidated Financial Statements
*			Management contracts or compensation plans or arrangements in which directors or executive officers participate.

3336

Large accelerated filer

Accelerated filer

Non-accelerated filer

o (Do not check if a smaller reporting company)

Smaller reporting company

Filing Compare · ADVISORY BOARD CO